{"gene":"GRK2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2003,"finding":"RKIP (Raf kinase inhibitor protein) is a physiological inhibitor of GRK2. After GPCR stimulation, PKC phosphorylates RKIP at Ser153, causing RKIP to dissociate from Raf-1 and associate with GRK2, blocking GRK2 activity and inhibiting receptor internalization.","method":"Co-immunoprecipitation, PKC phosphorylation assay, cardiomyocyte functional studies, RKIP knockdown","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, phosphorylation site identified, functional validation in cardiomyocytes, multiple orthogonal methods","pmids":["14654844"],"is_preprint":false},{"year":1999,"finding":"ERK1/2 phosphorylates GRK2 at Ser670, a C-terminal residue in an ERK consensus sequence, impairing GRK2 ability to phosphorylate both soluble and membrane-incorporated receptor substrates and dramatically attenuating Gβγ-mediated activation of GRK2.","method":"Mass spectrometry, mutational analysis, in vitro ERK1 phosphorylation assay, HEK293 cell kinase activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, mass spectrometry site identification, mutagenesis, and cell-based validation with multiple orthogonal methods","pmids":["10574913"],"is_preprint":false},{"year":2000,"finding":"PKC phosphorylates GRK2 at Ser29, located in the calmodulin-binding region. Calmodulin tonically inhibits GRK2, and PKC-mediated phosphorylation at Ser29 abolishes calmodulin inhibition of GRK2 kinase activity.","method":"In vitro PKC phosphorylation assay, 2D peptide mapping, HPLC-MS site identification, S29A mutagenesis, HEK293 cell transfection, calmodulin binding/inhibition assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, MS-based site identification, mutagenesis, and cell-based validation in single rigorous study","pmids":["11042191"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structure of the NTSR1–GRK2–Gαq complex with arrestin-biased ligand SBI-553 reveals that the N-terminal helix of GRK2 docks into the open cytoplasmic pocket of the receptor (analogous to G protein binding). SBI-553 binds at the GRK2–NTSR1 interface to enhance GRK2 binding while clashing with Gαq binding, providing a structural basis for arrestin-biased signaling.","method":"Cryo-EM structure determination","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structure with functional interpretation, single rigorous study","pmids":["37532940"],"is_preprint":false},{"year":2011,"finding":"GRK2 directly associates with and phosphorylates HDAC6, stimulating its α-tubulin deacetylase activity. Phosphorylation of GRK2 at S670 specifically potentiates this interaction. GRK2 and HDAC6 co-localize in lamellipodia of migrating cells, promoting local tubulin deacetylation and enhanced cell motility.","method":"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site mutagenesis (K220R, S670A), live-cell imaging, migration assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vitro phosphorylation, mutagenesis, localization with functional consequence, multiple orthogonal methods","pmids":["22193721"],"is_preprint":false},{"year":2004,"finding":"GRK2 functions as a negative regulator of insulin-stimulated GLUT4 translocation via its RGS domain, which sequesters activated Gαq/11. A GRK2 mutant lacking the RGS domain has no effect on insulin-stimulated glucose transport.","method":"Microinjection of anti-GRK2 antibody, siRNA knockdown, adenovirus-mediated overexpression of wild-type and kinase-deficient GRK2, RGS domain deletion mutant, 2-deoxyglucose uptake assay, GLUT4 translocation assay in 3T3-L1 adipocytes","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal loss-of-function and gain-of-function approaches with domain-specific mutant establishing mechanism","pmids":["15241473"],"is_preprint":false},{"year":2004,"finding":"GRK2 phosphorylates the C-terminus of the ENaC β-subunit, rendering ENaC channels insensitive to inhibition by the ubiquitin ligase Nedd4-2, thereby maintaining channels in the active state.","method":"Electrophysiology (Xenopus oocyte expression), in vitro kinase assay, co-expression studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation assay and functional electrophysiology readout in single study","pmids":["15284439"],"is_preprint":false},{"year":2009,"finding":"GRK2 protein levels are transiently down-regulated during G2/M transition via CDK2-mediated phosphorylation of GRK2 at Ser670, which triggers binding to the prolyl-isomerase Pin1 and subsequent proteasomal degradation. Prevention of this phosphorylation markedly delays cell cycle progression.","method":"Cell synchronization assays, CDK2 in vitro phosphorylation, S670A mutagenesis, Pin1 co-immunoprecipitation, flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro phosphorylation, Co-IP, mutagenesis, and cell cycle analysis with multiple orthogonal methods","pmids":["20080565"],"is_preprint":false},{"year":2009,"finding":"GRK2 interacts with PTCH1 (patched homolog 1) at residues 262-379, reducing PTCH1 association with cyclin B1 and disrupting PTCH1-mediated inhibition of cyclin B1 nuclear translocation. This function is kinase activity-independent and is required for normal zebrafish early embryonic development.","method":"Zebrafish GRK2 morpholino knockdown, rescue with kinase-dead K220R mutant, co-immunoprecipitation, deletion mutagenesis, cell cycle and proliferation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo rescue experiments, Co-IP, domain mapping, cell cycle assays, multiple orthogonal methods","pmids":["19502428"],"is_preprint":false},{"year":2006,"finding":"c-Src phosphorylates GRK2 on tyrosine residues (Y13, Y86, Y92) in the RGS-homology region, which increases GRK2 interaction with Gαq and enhances inhibition of the Gαq/phospholipase Cβ signaling pathway.","method":"Co-immunoprecipitation, tyrosine phosphorylation site mutagenesis (Y13,86,92F), phosphomimetic mutant, M1 muscarinic receptor stimulation assay, PLC-β signaling assay in cells","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and mutagenesis in single lab, functional signaling readout","pmids":["16725308"],"is_preprint":false},{"year":1998,"finding":"GRK2 directly binds tubulin via its C-terminal domain (residues 467-689) and phosphorylates tubulin (Km ~3 µM, 1.3 mol phosphate/dimer). Tubulin and Gβγ bind GRK2 independently. GRK2-mediated tubulin phosphorylation is stimulated by Gβγ and agonist-activated muscarinic receptors.","method":"GST pulldown, co-purification via tubulin polymerization-depolymerization, in vitro kinase assay, Western blot","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution with direct kinase assay and pulldown, single lab","pmids":["9716377"],"is_preprint":false},{"year":1995,"finding":"GRK2 requires acidic phospholipids for phosphorylation of the β2-adrenergic receptor; phospholipids increase catalytic activity via a conformational change in the kinase without altering Km for peptide substrate. PIP2 inhibits GRK2 activity and reduces crosslinker incorporation.","method":"Mixed micelle phosphorylation assay, photoaffinity crosslinking with [125I]ACTP, Km determination, proteolytic mapping","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mechanistic crosslinking and kinetics, single lab","pmids":["7673171"],"is_preprint":false},{"year":2009,"finding":"GRK2 directly phosphorylates p38 MAPK at Thr123, a residue at the entrance of a docking groove. The phosphomimetic T123E mutant of p38 shows reduced binding to MKK6 and impaired p38 activation, and elevated GRK2 levels downregulate p38-dependent cellular responses.","method":"In vitro kinase assay, phosphomimetic mutagenesis (T123E), MKK6 co-immunoprecipitation, substrate phosphorylation assays (MEF2, MK2, ATF2), macrophage cytokine assay in GRK2+/- mice","journal":"Journal of receptor and signal transduction research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phosphorylation, mutagenesis, and Co-IP; in vivo validation with GRK2+/- mice; single lab","pmids":["18437630"],"is_preprint":false},{"year":2009,"finding":"GRK2 localizes to centrosomes and, upon EGF stimulation, directly phosphorylates and activates the kinase Mst2, which drives EGFR-mediated centrosome separation in a Nek2A-dependent manner.","method":"Immunofluorescence localization, GRK2 knockdown, in vitro kinase assay (GRK2 phosphorylation of Mst2), dominant-negative Mst2, centrosome separation assay","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro phosphorylation, localization with functional consequence, dominant-negative validation; single lab","pmids":["23904266"],"is_preprint":false},{"year":2009,"finding":"GRK2 negatively regulates WNT/β-catenin (canonical Wnt) signaling by binding APC via its RGS domain. GRK2 enzymatic activity is required for the GRK2-APC interaction and for inhibition of β-catenin stabilization and nuclear translocation. RGS domain deletion abolishes both the APC interaction and inhibition of Wnt signaling.","method":"Reporter assay (Wnt-responsive luciferase), co-immunoprecipitation, siRNA knockdown of endogenous GRK2, RGS domain deletion mutant, β-catenin immunofluorescence in calvarial osteoblasts","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping, siRNA, functional reporter assay; single lab","pmids":["19556343"],"is_preprint":false},{"year":2015,"finding":"GRK2 selectively phosphorylates only C-terminal Ser residues of agonist-activated neurotensin receptor 1 (NTSR1) in nanodiscs, in an agonist-dependent manner. Negatively charged lipids in the vicinity of NTSR1 directly affect the extent of GRK2-mediated phosphorylation. GRK2 does not require acidic residues upstream of phospho-acceptors for NTSR1 (unlike β2AR and μOR).","method":"In vitro phosphorylation in nanodiscs, mass spectrometry phosphosite mapping, NTSR1 mutational analysis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in nanodiscs with MS-based phosphosite mapping and mutagenesis; single rigorous study","pmids":["26120872"],"is_preprint":false},{"year":2016,"finding":"GRK2 promotes breast cancer progression via phosphorylation and activation of HDAC6, which deacetylates Pin1, enhancing Pin1 stability and its interactions with mitotic regulators. This GRK2/HDAC6/Pin1 axis promotes proliferation and anchorage-independent growth.","method":"Co-immunoprecipitation, GRK2 knockdown/overexpression, in vitro HDAC6 phosphorylation, Pin1 acetylation assay, tumor xenograft in mice","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, in vitro phosphorylation, in vivo xenograft, multiple orthogonal methods; single lab","pmids":["27720394"],"is_preprint":false},{"year":2014,"finding":"Insulin stimulates GRK2 recruitment to β2AR via an IRS2-dependent mechanism. GRK2 phosphorylates β2AR at GRK sites Ser355/356, promoting β2AR internalization and suppressing βAR-induced cAMP-PKA signaling and contractile response in cardiomyocytes.","method":"Co-immunoprecipitation, β2AR phosphorylation assay, β2AR internalization assay, cAMP assay, IRS2 knockout mouse cardiomyocytes, contractility measurement","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, site-specific phosphorylation, receptor internalization, genetic KO; single lab","pmids":["25460042"],"is_preprint":false},{"year":2007,"finding":"GRK2 directly interacts with and phosphorylates both Nedd4 and Nedd4-2 at multiple sites, including Thr466 in Nedd4 located in the ww3 domain region that binds ENaC, providing a mechanism for GRK2 regulation of sodium transport.","method":"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site identification","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phosphorylation and Co-IP; single lab, limited follow-up","pmids":["17544362"],"is_preprint":false},{"year":2009,"finding":"GRK2 activation by receptor requires residues in the C-tail region of the kinase, particularly Val477. The V477D mutant shows a 12-fold lower kcat with no change in Km, indicating a defect in acquiring the closed (active) kinase conformation, and is resistant to activation by agonist-bound β2AR.","method":"Site-directed mutagenesis, in vitro kinase assay with Michaelis-Menten kinetics, rhodopsin and β2AR phosphorylation assay","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with kinetic analysis and structure-guided mutagenesis; single lab","pmids":["19338266"],"is_preprint":false},{"year":2018,"finding":"GRK2 phosphorylation at Ser670 is required for GRK2 translocation to mitochondria post-ischemia-reperfusion injury. Mice with S670A knock-in show reduced cardiomyocyte death and better cardiac function post-IR, and cultured S670A cardiomyocytes maintain pyruvate dehydrogenase activity and glucose oxidation after IR.","method":"S670A knock-in mice, cardiac IR model, cardiomyocyte death assay, mitochondrial respiration assay, pyruvate dehydrogenase activity measurement","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse model, mechanistic biochemical assays, multiple readouts in single rigorous study","pmids":["30538174"],"is_preprint":false},{"year":2016,"finding":"An essential role for GRK2 kinase activity in Hedgehog signaling downstream of Smoothened (Smo) is established in zebrafish; grk2-null embryos are unresponsive to Shh and oncogenic Smo but remain responsive to PKA inhibition.","method":"Zebrafish grk2 loss-of-function mutants, kinase-dead rescue experiments, Smo phosphomimetic and phospho-null mutant analysis","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic epistasis in zebrafish with kinase-dead rescue; single lab","pmids":["27113758"],"is_preprint":false},{"year":2024,"finding":"GRK2 relocates from the ciliary base to the ciliary shaft upon Smoothened activation, phosphorylates SMO, and enables active SMO to directly bind and inactivate the PKA catalytic subunit, initiating downstream Hedgehog signal transduction.","method":"Live-cell imaging of GRK2 relocalization in primary cilia, reconstitution studies, SMO phosphorylation assay, PKA-C binding assay, in vivo zebrafish and mouse models","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reconstitution, localization with functional consequence, in vivo validation in two organisms, multiple orthogonal methods","pmids":["39138140"],"is_preprint":false},{"year":2020,"finding":"Loss-of-function mutations in GRK2 (ADRBK1) cause Jeune syndrome (asphyxiating thoracic dystrophy) by impairing cilia-based Hedgehog signaling and canonical Wnt signaling, specifically through failure to phosphorylate the Wnt co-receptor LRP6.","method":"Patient-derived GRK2 null cells, chondrocyte differentiation assay, Hedgehog pathway reporter, canonical Wnt reporter, LRP6 phosphorylation assay","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived cells, pathway reporter assays, phosphorylation assay; single lab","pmids":["33200460"],"is_preprint":false},{"year":2017,"finding":"GRK2 interacts with and phosphorylates monoamine oxidase AMX-2 in C. elegans, promoting its function. Loss of grk-2 leads to elevated AMX-2 and increased serotonin metabolism (5-HT→5-HIAA), causing egg-laying defects that are rescued by wild-type but not catalytically inactive GRK-2.","method":"C. elegans grk-2 loss-of-function genetics, serotonin/5-HIAA metabolite measurements, co-immunoprecipitation, GRK-2 phosphorylation of AMX-2, cell-specific rescue experiments","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, in vitro phosphorylation, genetic rescue with kinase-dead control; single lab in C. elegans ortholog","pmids":["28213524"],"is_preprint":false},{"year":2015,"finding":"GRK2 suppresses transcription of the mPeriod1 gene and physically interacts with PERIOD1 and PERIOD2 proteins to promote PERIOD2 phosphorylation at Ser545, impeding PERIOD1/2 nuclear trafficking and modulating circadian clock period and amplitude.","method":"Grk2-deficient mouse behavioral rhythms, SCN electrophysiology, GRK2 Co-IP with PER1/2, in vitro phosphorylation (Ser545), transcriptional reporter assay, nuclear trafficking assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, in vitro phosphorylation site mapping, in vivo Grk2 KO phenotype, multiple orthogonal methods; single lab","pmids":["26279567"],"is_preprint":false},{"year":2020,"finding":"GRK2 is found to naively associate with plasma membrane delta opioid receptor (DOR) in peripheral sensory neurons, inhibiting Gβ subunit association and reducing DOR activity. Bradykinin-activated PKC phosphorylates RKIP, sequestering GRK2 away from DOR onto RKIP, restoring DOR functionality.","method":"Co-immunoprecipitation in sensory neurons, DOR functional assay, PKC inhibition, RKIP phosphorylation assay, GRK2-RKIP pulldown","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, functional receptor assay, pharmacological dissection; single lab","pmids":["27568556"],"is_preprint":false},{"year":2018,"finding":"The dopamine D2 receptor (D2R) can directly recruit GRK2 in a G protein-independent manner. Using βarr-preferring D2R mutants and the biased ligand UNC9994, direct GRK2 recruitment was shown to drive β-arrestin pathway activation without G protein activation.","method":"BRET-based recruitment assay, biased D2R mutants (G protein-preferring and βarr-preferring), pharmacological G protein blockade, βarr2 recruitment assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BRET assay with multiple engineered receptor and ligand tools; single lab","pmids":["29487132"],"is_preprint":false},{"year":2020,"finding":"GRK2 and GRK3 are the primary kinases required for μ-opioid receptor (μ-OR) internalization and β-arrestin2 recruitment in HEK293 cells; GRK2 is more important than GRK3 for these processes. A GRK2/3-independent component of sustained β-arrestin2 plasma membrane recruitment also exists.","method":"CRISPR/Cas9 GRK2, GRK3, and GRK2/3 double knockout HEK293 cells, μ-OR internalization assay, β-arrestin2 recruitment assay, rescue expression, CMPD101 pharmacological inhibition","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO, rescue experiments, and pharmacological cross-validation; multiple orthogonal methods","pmids":["33060647"],"is_preprint":false},{"year":2019,"finding":"GRK2 is degraded at early ischemia-reperfusion via proteasome (during ischemia) and calpain (during reperfusion) following successive phosphorylation at specific sites. Preventing this degradation with calpain and proteasome inhibitors preserves AKT pathway activity and reduces I/R injury.","method":"Isolated rat and porcine heart I/R models, immunoblotting for GRK2 protein, proteasome and calpain inhibitor treatment, Pin1/AKT pathway analysis","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two animal model systems, pharmacological intervention with mechanistic readout; single lab","pmids":["31594751"],"is_preprint":false},{"year":2019,"finding":"Calpain activation by isoproterenol increases GRK2 protein levels by degrading GRK2's ubiquitin ligase MDM2 (stabilizing GRK2) and by enhancing NF-κB-dependent GRK2 transcription via IκB proteolysis. Genetic downregulation of GRK2 prevents isoproterenol-mediated hypertrophy independently of calpain inhibition.","method":"Calpain inhibitor (SNJ-1945) in rats and GRK2 hemizygous mice, MDM2 protein assay, NF-κB/IκB western blot, GRK2 mRNA quantification, cardiac hypertrophy morphological/biochemical markers","journal":"Basic research in cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological approaches, mechanistic pathway dissection; single lab","pmids":["30915659"],"is_preprint":false},{"year":2020,"finding":"GRK5 phosphorylates and inhibits the mineralocorticoid receptor (MR) in cardiomyocytes following β2AR activation, suppressing aldosterone-induced MR transcriptional activity, whereas GRK2 phosphorylates and desensitizes GPER (G protein-coupled estrogen receptor).","method":"CRISPR/Cas9 GRK5 deletion in H9c2 cells, Co-IP of GRK5-MR, MR transcriptional reporter assay, GRK2 pharmacological inhibition, adult rat ventricular myocyte studies","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO, Co-IP, transcriptional reporter, functional cell biology; single lab","pmids":["32326036"],"is_preprint":false},{"year":2020,"finding":"GRK2 phosphorylates the mRNA-binding protein HuR, increasing HuR cytoplasmic shuttling and HuR binding to HIF-1α mRNA under hypoxia. GRK2-phosphodefective HuR mutants show defective cytosolic accumulation and lower HIF-1α mRNA binding.","method":"GRK2 in vitro phosphorylation of HuR, phosphodefective HuR mutagenesis, RIP assay (RNA immunoprecipitation) for HIF-1α mRNA, subcellular fractionation, VEGF-C assay","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phosphorylation, mutagenesis, RNA IP with functional readout; single lab","pmids":["32413989"],"is_preprint":false},{"year":2020,"finding":"GRK2 binds the death domain of MALT1 and inhibits both MALT1 scaffolding and proteolytic activities, suppressing NF-κB activation downstream of antigen receptor signaling. Lower GRK2 levels in ABC-DLBCL are associated with enhanced tumor growth in vitro and in vivo.","method":"Co-immunoprecipitation of GRK2-MALT1, MALT1 protease activity assay, NF-κB reporter assay, GRK2 knockdown, in vitro and in vivo tumor growth assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping, functional protease assay, in vivo tumor model; single lab","pmids":["31961340"],"is_preprint":false},{"year":2022,"finding":"GRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12 receptors; platelet-specific GRK2 deletion increases ADP-stimulated Ca2+ mobilization, Rap1 activation, Akt phosphorylation, integrin activation, and impairs ADP receptor desensitization. GRK2 also binds endogenous Gβγ subunits during platelet activation.","method":"Platelet-specific GRK2 knockout mice, laser-induced thrombosis model, platelet aggregation assay, Ca2+ mobilization assay, Rap1 activation assay, Akt phosphorylation, cAMP assay, Co-IP of GRK2-Gβγ","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, in vivo thrombosis model, multiple biochemical readouts, Gβγ Co-IP; multiple orthogonal methods","pmids":["35793439"],"is_preprint":false},{"year":2023,"finding":"GRK2 phosphorylates SAV1 (Salvador homolog-1), leading to SAV1 ubiquitination and degradation; this impairs Hippo-YAP pathway activity by reducing YAP phosphorylation, promoting YAP nuclear translocation and FLS proliferation in rheumatoid arthritis.","method":"GRK2 knockdown/overexpression, Co-immunoprecipitation of GRK2-SAV1, SAV1 ubiquitination assay, YAP phosphorylation and nuclear translocation assay, CIA rat model with paroxetine treatment","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, functional pathway readout, in vivo model; single lab","pmids":["38486990"],"is_preprint":false},{"year":2017,"finding":"EIF3d stabilizes GRK2 protein by blocking ubiquitin-mediated GRK2 degradation, thereby activating PI3K/Akt signaling and promoting gallbladder cancer cell proliferation and migration.","method":"Co-immunoprecipitation of EIF3d-GRK2, ubiquitination assay, GRK2 protein stability assay, PI3K/Akt signaling western blot, EIF3d knockdown/overexpression, in vitro and in vivo cancer assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, protein stability and signaling readouts; single lab","pmids":["28594409"],"is_preprint":false},{"year":1996,"finding":"GRK2 together with β-arrestin1 desensitizes the TSH receptor: co-transfection of GRK2 and/or β-arrestin1 reduces TSH-induced cAMP accumulation by 35-45% and blunts TSH-stimulated mitogenic activity in thyroid cells.","method":"COS7 cell co-transfection with TSH receptor + GRK2 ± β-arrestin1, cAMP accumulation assay, FRTL5 cell line stably overexpressing β-arrestin1, proliferation assay","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-transfection functional assay and stable cell line; single lab","pmids":["8885248"],"is_preprint":false},{"year":2010,"finding":"Reduced GRK2 specifically in microglia/monocytes is required and sufficient to transform acute carrageenan- or CCL3-induced hyperalgesia into chronic hyperalgesia, associated with ongoing microglial activation and increased phospho-p38 and TNF-α in the spinal cord. Separate reduction of GRK2 in Nav1.8 nociceptors increases but does not prolong hyperalgesia, and enhances CCL3-induced TRPV1 sensitization.","method":"Cre-Lox cell-specific GRK2 knockdown (LysM-Cre for microglia, Nav1.8-Cre for nociceptors), carrageenan/CCL3 hyperalgesia models, intrathecal p38/TNF-α/minocycline inhibition, TRPV1 sensitization assay","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-specific conditional KO, genetic epistasis, pharmacological pathway validation; multiple orthogonal methods","pmids":["20147541"],"is_preprint":false},{"year":2013,"finding":"Reduced nociceptor GRK2 promotes cAMP signaling to EPAC1, and the balance between GRK2 and EPAC1 levels determines whether acute hyperalgesia transitions to chronic pain. Viral gene transfer to increase GRK2 or EPAC1 heterozygosity prevents chronic PGE2-induced hyperalgesia in two priming models.","method":"Viral (HSV) GRK2 gene transfer, Epac1 heterozygous and antisense-ODN mice, two hyperalgesic priming models (carrageenan and ΨεRACK), CFA chronic pain model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — viral gene transfer, genetic mouse models, pharmacological validation; multiple orthogonal methods replicated in two priming models","pmids":["24231349"],"is_preprint":false}],"current_model":"GRK2 is a multifunctional serine/threonine kinase that canonically phosphorylates agonist-occupied GPCRs to initiate β-arrestin recruitment, receptor uncoupling, and internalization; its activity and localization are tightly regulated by phosphorylation (PKC at Ser29 relieving calmodulin inhibition; ERK/CDK2 at Ser670 promoting Pin1 binding and degradation or mitochondrial translocation; c-Src on tyrosines enhancing Gαq binding), by lipid cofactors and Gβγ; and by interacting proteins (RKIP, calmodulin). Beyond GPCR desensitization, GRK2 directly phosphorylates non-receptor substrates including HDAC6 (regulating tubulin deacetylation and cell motility), p38 MAPK, Mst2, tubulin, ENaC β-subunit, Nedd4/Nedd4-2, HuR, SAV1, and PERIOD2, and it acts as a scaffold/RGS-domain inhibitor of Gαq and WNT/APC signaling, and as an inhibitor of MALT1 protease activity; in the primary cilium GRK2 phosphorylates Smoothened to enable direct PKA catalytic subunit binding and Hedgehog pathway activation; and its subcellular localization to mitochondria (Ser670-dependent), centrosomes, and lamellipodia underlies cell-type-specific roles in metabolism, cell division, and migration."},"narrative":{"mechanistic_narrative":"GRK2 is a multifunctional serine/threonine kinase that initiates agonist-dependent GPCR desensitization and, beyond this canonical role, acts as a phosphorylation- and scaffold-based regulator of cell migration, division, metabolism, developmental signaling, and circadian and pain physiology [PMID:33060647, PMID:26120872, PMID:22193721]. In its receptor-directed mode, GRK2 is the primary kinase driving µ-opioid receptor internalization and β-arrestin2 recruitment [PMID:33060647], selectively phosphorylates C-terminal serines of agonist-activated receptors such as NTSR1 in a lipid-influenced manner [PMID:26120872], and can be recruited directly by receptors (e.g. the D2 dopamine receptor) in a G-protein-independent fashion to bias signaling toward β-arrestin [PMID:29487132]; a cryo-EM structure of the NTSR1–GRK2–Gαq complex shows the GRK2 N-terminal helix docking into the receptor cytoplasmic pocket analogously to G protein, with the biased ligand SBI-553 binding the GRK2–NTSR1 interface to favor GRK2 over Gαq [PMID:37532940]. GRK2 catalytic competence depends on a C-tail conformational switch (Val477) that acquires the closed active state upon receptor engagement [PMID:19338266] and on acidic phospholipid cofactors that activate the kinase while PIP2 inhibits it [PMID:7673171]. GRK2 also acts through its RGS domain to sequester activated Gαq/11, negatively regulating insulin-stimulated GLUT4 translocation, and to bind APC and inhibit canonical WNT/β-catenin signaling [PMID:15241473, PMID:19556343]. A broad set of non-receptor substrates extends its reach: GRK2 phosphorylates and activates HDAC6 to promote tubulin deacetylation, lamellipodial motility, and (via HDAC6/Pin1 deacetylation) tumor proliferation [PMID:22193721, PMID:27720394]; phosphorylates p38 MAPK at Thr123 to dampen p38 signaling [PMID:18437630]; activates Mst2 to drive centrosome separation [PMID:23904266]; and phosphorylates ENaC and its regulator Nedd4/Nedd4-2, the mRNA-binding protein HuR, SAV1 in the Hippo–YAP pathway, and PERIOD2 to set circadian period [PMID:15284439, PMID:17544362, PMID:32413989, PMID:38486990, PMID:26279567]. In the primary cilium GRK2 relocates to the ciliary shaft upon Smoothened activation, phosphorylates SMO, and enables active SMO to bind and inactivate the PKA catalytic subunit, transducing Hedgehog signaling [PMID:39138140, PMID:27113758]. GRK2 activity, levels, and localization are tightly controlled: PKC at Ser29 relieves calmodulin inhibition [PMID:11042191], ERK and CDK2 at Ser670 impair kinase activity, trigger Pin1-dependent degradation during G2/M, and direct mitochondrial translocation after cardiac ischemia-reperfusion [PMID:10574913, PMID:11042191, PMID:20080565, PMID:30538174]; c-Src tyrosine phosphorylation enhances Gαq binding [PMID:16725308]; and RKIP serves as a physiological inhibitor that sequesters GRK2 from receptors following PKC-dependent activation [PMID:14654844, PMID:27568556]. Loss-of-function mutations in GRK2 cause Jeune syndrome (asphyxiating thoracic dystrophy) through failed cilia-based Hedgehog signaling and failed phosphorylation of the WNT co-receptor LRP6 [PMID:33200460].","teleology":[{"year":1995,"claim":"Established that GRK2 catalytic activity toward GPCRs is not intrinsic but conditioned by membrane lipids, defining a biochemical activation requirement.","evidence":"Mixed-micelle phosphorylation, photoaffinity crosslinking and kinetics on β2AR","pmids":["7673171"],"confidence":"Medium","gaps":["Structural basis of the lipid-induced conformational change not resolved","PIP2 inhibition mechanism not defined at residue level"]},{"year":1996,"claim":"Demonstrated that GRK2 cooperates with β-arrestin1 to desensitize a GPCR, anchoring its canonical receptor-uncoupling role functionally.","evidence":"Co-transfection of TSH receptor with GRK2/β-arrestin1, cAMP and proliferation assays","pmids":["8885248"],"confidence":"Medium","gaps":["Direct receptor phosphorylation sites not mapped","Overexpression system may not reflect endogenous stoichiometry"]},{"year":1998,"claim":"Identified the first non-receptor GRK2 substrate (tubulin), opening the concept that GRK2 acts beyond GPCR desensitization.","evidence":"GST pulldown, in vitro kinase assay, co-purification with tubulin","pmids":["9716377"],"confidence":"Medium","gaps":["Functional consequence of tubulin phosphorylation in cells not established","Single-lab in vitro reconstitution"]},{"year":1999,"claim":"Showed that ERK1/2 phosphorylation at Ser670 is a feedback brake that impairs GRK2 receptor phosphorylation and Gβγ activation, establishing kinase regulation of the kinase.","evidence":"Mass spectrometry site ID, mutagenesis, in vitro ERK1 assay, HEK293 activity assays","pmids":["10574913"],"confidence":"High","gaps":["Did not address downstream localization or degradation consequences of S670 phosphorylation"]},{"year":2000,"claim":"Defined PKC phosphorylation of Ser29 as the switch that relieves tonic calmodulin inhibition, linking PKC activity to GRK2 activation.","evidence":"In vitro PKC assay, peptide mapping, S29A mutagenesis, calmodulin binding assay","pmids":["11042191"],"confidence":"High","gaps":["Cellular contexts where calmodulin inhibition dominates not delineated"]},{"year":2003,"claim":"Identified RKIP as a physiological inhibitor that, upon PKC phosphorylation, switches from Raf-1 to GRK2 to block receptor internalization, providing endogenous GRK2 regulation.","evidence":"Reciprocal Co-IP, PKC phosphorylation, RKIP knockdown, cardiomyocyte function","pmids":["14654844"],"confidence":"High","gaps":["Quantitative contribution of RKIP across receptor types not defined"]},{"year":2004,"claim":"Established the RGS domain of GRK2 as a Gαq/11 sequestration module that negatively regulates insulin/GLUT4 metabolism independent of kinase activity.","evidence":"Antibody microinjection, siRNA, RGS-deletion mutant, glucose uptake in 3T3-L1 adipocytes","pmids":["15241473"],"confidence":"High","gaps":["Direct structural basis of Gαq sequestration in this context not shown"]},{"year":2004,"claim":"Showed GRK2 phosphorylates the ENaC β-subunit to render the channel Nedd4-2-insensitive, extending GRK2 to ion transport regulation.","evidence":"Xenopus oocyte electrophysiology, in vitro kinase assay, co-expression","pmids":["15284439"],"confidence":"High","gaps":["Phosphosite on ENaC β not precisely mapped in original finding","In vivo relevance to sodium handling not established here"]},{"year":2006,"claim":"Defined c-Src tyrosine phosphorylation (Y13/86/92) of the RGS region as a positive modulator of Gαq binding, adding tyrosine-kinase control of GRK2.","evidence":"Co-IP, tyrosine site mutagenesis, phosphomimetic, M1 receptor/PLC-β signaling","pmids":["16725308"],"confidence":"Medium","gaps":["Single lab; physiological c-Src context not defined"]},{"year":2007,"claim":"Identified Nedd4/Nedd4-2 as direct GRK2 substrates, providing a mechanistic link between GRK2 and ubiquitin-ligase control of sodium transport.","evidence":"Co-IP, in vitro kinase assay, phosphosite identification (Thr466)","pmids":["17544362"],"confidence":"Medium","gaps":["Functional impact on Nedd4 ligase activity not quantified","Limited follow-up"]},{"year":2009,"claim":"Connected ERK/CDK2-driven Ser670 phosphorylation to Pin1-dependent proteasomal degradation during G2/M, showing GRK2 turnover gates cell cycle progression.","evidence":"Cell synchronization, CDK2 in vitro phosphorylation, S670A mutagenesis, Pin1 Co-IP, flow cytometry","pmids":["20080565"],"confidence":"High","gaps":["E3 ligase mediating Ser670/Pin1-dependent degradation not identified here"]},{"year":2009,"claim":"Revealed a kinase-independent scaffolding role: GRK2 binds PTCH1 to release cyclin B1 nuclear translocation, required for embryonic development.","evidence":"Zebrafish morpholino, kinase-dead rescue, Co-IP, domain mapping","pmids":["19502428"],"confidence":"High","gaps":["Mammalian relevance of PTCH1–cyclin B1 control not demonstrated"]},{"year":2009,"claim":"Established GRK2 as a centrosomal kinase that activates Mst2 to drive EGFR-mediated centrosome separation, linking GRK2 to mitotic architecture.","evidence":"Immunofluorescence localization, knockdown, in vitro Mst2 phosphorylation, dominant-negative","pmids":["23904266"],"confidence":"Medium","gaps":["Single lab; centrosomal recruitment mechanism unknown"]},{"year":2009,"claim":"Showed GRK2 phosphorylates p38 MAPK at Thr123 to impair MKK6 binding and p38 activation, defining a kinase-substrate node dampening inflammatory signaling.","evidence":"In vitro kinase assay, T123E mutagenesis, MKK6 Co-IP, GRK2+/- macrophage cytokine assays","pmids":["18437630"],"confidence":"Medium","gaps":["Endogenous stoichiometry of p38 phosphorylation by GRK2 unclear"]},{"year":2009,"claim":"Defined a kinase-activity-dependent RGS-domain interaction with APC that inhibits canonical WNT/β-catenin signaling, broadening GRK2 into developmental signaling.","evidence":"Wnt luciferase reporter, Co-IP, siRNA, RGS-deletion, β-catenin imaging in osteoblasts","pmids":["19556343"],"confidence":"Medium","gaps":["How kinase activity enables a scaffolding interaction not resolved"]},{"year":2009,"claim":"Defined the C-tail residue Val477 as required for acquiring the closed active kinase conformation upon receptor engagement, providing a conformational activation mechanism.","evidence":"Structure-guided mutagenesis, kinetic analysis, rhodopsin/β2AR phosphorylation","pmids":["19338266"],"confidence":"Medium","gaps":["Direct structural snapshot of the closed state not provided in this study"]},{"year":2010,"claim":"Demonstrated cell-type-specific GRK2 dosage controls chronic pain: reduced microglial GRK2 converts acute to chronic hyperalgesia via p38/TNF-α.","evidence":"Cell-specific conditional knockdown, hyperalgesia models, intrathecal pathway inhibition","pmids":["20147541"],"confidence":"High","gaps":["Molecular substrate of GRK2 in microglia not identified"]},{"year":2011,"claim":"Identified HDAC6 as a GRK2 substrate whose activation promotes tubulin deacetylation and cell motility, with Ser670 phosphorylation potentiating the interaction.","evidence":"Reciprocal Co-IP, in vitro kinase assay, K220R/S670A mutagenesis, live-cell imaging, migration assay","pmids":["22193721"],"confidence":"High","gaps":["HDAC6 phosphosite(s) targeted by GRK2 not pinpointed here"]},{"year":2013,"claim":"Showed the GRK2/EPAC1 balance in nociceptors determines transition to chronic pain, establishing GRK2 as a rheostat in pain priming.","evidence":"Viral GRK2 gene transfer, Epac1 heterozygous/antisense mice, two priming models","pmids":["24231349"],"confidence":"High","gaps":["Direct molecular link between GRK2 levels and cAMP/EPAC1 not biochemically defined"]},{"year":2014,"claim":"Connected insulin signaling to GRK2-mediated β2AR desensitization via IRS2-dependent recruitment, linking metabolic and adrenergic signaling in heart.","evidence":"Co-IP, β2AR phosphorylation/internalization, cAMP, IRS2 KO cardiomyocytes, contractility","pmids":["25460042"],"confidence":"Medium","gaps":["Single lab; molecular detail of IRS2–GRK2 coupling incomplete"]},{"year":2015,"claim":"Refined GRK2 substrate selectivity, showing agonist- and lipid-dependent C-terminal serine phosphorylation of NTSR1 differing from β2AR/µOR consensus rules.","evidence":"Nanodisc phosphorylation, MS phosphosite mapping, NTSR1 mutagenesis","pmids":["26120872"],"confidence":"High","gaps":["Generality of lipid-tuned phosphosite selection across receptors unknown"]},{"year":2015,"claim":"Placed GRK2 in the circadian machinery by phosphorylating PERIOD2 at Ser545 and suppressing mPeriod1 transcription to modulate clock period and amplitude.","evidence":"Grk2-deficient mouse rhythms, SCN electrophysiology, PER1/2 Co-IP, in vitro phosphorylation, reporter assay","pmids":["26279567"],"confidence":"Medium","gaps":["Mechanism of transcriptional suppression of Period1 not defined"]},{"year":2016,"claim":"Established a GRK2/HDAC6/Pin1 axis promoting breast cancer proliferation, linking GRK2's HDAC6 activation to oncogenic Pin1 stabilization.","evidence":"Co-IP, knockdown/overexpression, in vitro HDAC6 phosphorylation, Pin1 acetylation, xenograft","pmids":["27720394"],"confidence":"Medium","gaps":["Single lab; relative contribution of this axis among GRK2 oncogenic functions unclear"]},{"year":2016,"claim":"Demonstrated GRK2 kinase activity is essential for Hedgehog signaling downstream of Smoothened in vivo, placing GRK2 in the Hh pathway.","evidence":"Zebrafish grk2-null, kinase-dead rescue, Smo phosphomimetic/phospho-null analysis","pmids":["27113758"],"confidence":"Medium","gaps":["Molecular mechanism downstream of Smo phosphorylation not resolved in this study"]},{"year":2017,"claim":"Identified the ciliary/serotonergic role via the GRK2 ortholog phosphorylating monoamine oxidase AMX-2 in C. elegans, controlling serotonin metabolism and egg-laying.","evidence":"C. elegans grk-2 genetics, metabolite measurement, Co-IP, kinase-dead rescue","pmids":["28213524"],"confidence":"Medium","gaps":["Mammalian MAO regulation by GRK2 not tested"]},{"year":2017,"claim":"Showed EIF3d stabilizes GRK2 by blocking ubiquitin-mediated degradation, activating PI3K/Akt to drive gallbladder cancer, adding a translation-factor controller of GRK2 levels.","evidence":"Co-IP, ubiquitination/stability assays, PI3K/Akt western, in vitro/in vivo cancer assays","pmids":["28594409"],"confidence":"Medium","gaps":["E3 ligase blocked by EIF3d not identified"]},{"year":2018,"claim":"Demonstrated D2R can directly recruit GRK2 G-protein-independently to drive β-arrestin signaling, refining the concept of GRK2-driven biased agonism.","evidence":"BRET recruitment, biased D2R mutants, biased ligand UNC9994, G-protein blockade","pmids":["29487132"],"confidence":"Medium","gaps":["Structural basis of direct GRK2 recruitment not defined here"]},{"year":2018,"claim":"Defined Ser670 phosphorylation as the determinant of GRK2 mitochondrial translocation after ischemia-reperfusion, linking GRK2 to cardiomyocyte metabolic injury.","evidence":"S670A knock-in mice, cardiac IR model, mitochondrial respiration, PDH activity","pmids":["30538174"],"confidence":"High","gaps":["Mitochondrial substrate(s) of GRK2 not identified"]},{"year":2019,"claim":"Mapped phosphorylation-triggered proteasomal (ischemia) and calpain (reperfusion) degradation of GRK2, showing GRK2 turnover modulates AKT-dependent cardioprotection.","evidence":"Rat/porcine heart IR, proteasome/calpain inhibitors, Pin1/AKT analysis","pmids":["31594751"],"confidence":"Medium","gaps":["Specific phosphosites driving each degradation route not fully resolved"]},{"year":2019,"claim":"Showed calpain raises GRK2 levels by degrading its ligase MDM2 and via NF-κB transcription, mechanistically tying GRK2 abundance to cardiac hypertrophy.","evidence":"Calpain inhibitor in rats, GRK2 hemizygous mice, MDM2/NF-κB/IκB assays, mRNA quantification","pmids":["30915659"],"confidence":"Medium","gaps":["Direct MDM2-mediated GRK2 ubiquitination not shown in this study"]},{"year":2020,"claim":"Established with CRISPR knockouts that GRK2 is the dominant kinase for µ-OR internalization and β-arrestin2 recruitment, quantifying its primacy among GRKs.","evidence":"GRK2/GRK3/double KO HEK293, internalization and βarr2 recruitment, rescue, CMPD101","pmids":["33060647"],"confidence":"High","gaps":["Identity of the GRK2/3-independent sustained recruitment component unknown"]},{"year":2020,"claim":"Demonstrated GRK2 binds the MALT1 death domain to inhibit its scaffolding and protease activities, suppressing NF-κB and acting as a tumor suppressor in ABC-DLBCL.","evidence":"Co-IP/domain mapping, MALT1 protease assay, NF-κB reporter, knockdown, tumor models","pmids":["31961340"],"confidence":"Medium","gaps":["Whether GRK2 kinase activity contributes to MALT1 inhibition not resolved"]},{"year":2020,"claim":"Showed GRK2 phosphorylates HuR to enhance its cytoplasmic shuttling and HIF-1α mRNA binding under hypoxia, linking GRK2 to post-transcriptional control.","evidence":"In vitro phosphorylation, phosphodefective HuR mutants, RIP for HIF-1α mRNA, fractionation","pmids":["32413989"],"confidence":"Medium","gaps":["HuR phosphosite(s) targeted by GRK2 not precisely defined"]},{"year":2020,"claim":"Established a peripheral neuronal switch in which GRK2 tonically inhibits delta opioid receptor until PKC-phosphorylated RKIP sequesters it, restoring receptor function.","evidence":"Sensory neuron Co-IP, DOR functional assay, PKC inhibition, GRK2-RKIP pulldown","pmids":["27568556"],"confidence":"Medium","gaps":["Single lab; generalizability to other receptors not tested"]},{"year":2020,"claim":"Distinguished GRK isoform specificity in cardiomyocytes, with GRK2 phosphorylating and desensitizing GPER, refining receptor-selective GRK roles.","evidence":"CRISPR GRK5 deletion, Co-IP, MR reporter, GRK2 pharmacological inhibition, ventricular myocytes","pmids":["32326036"],"confidence":"Medium","gaps":["GRK2–GPER phosphosites and functional output not detailed"]},{"year":2020,"claim":"Linked GRK2 loss-of-function mutations to Jeune syndrome through failed cilia-based Hedgehog and LRP6-dependent canonical Wnt signaling, providing a human disease mechanism.","evidence":"Patient-derived GRK2-null cells, chondrocyte differentiation, Hh/Wnt reporters, LRP6 phosphorylation","pmids":["33200460"],"confidence":"Medium","gaps":["Direct evidence that GRK2 phosphorylates LRP6 in vivo limited","Genotype–phenotype range not defined"]},{"year":2022,"claim":"Showed GRK2 desensitizes platelet ADP receptors P2Y1/P2Y12 and binds endogenous Gβγ, establishing its role in thrombosis and Ca2+/Rap1/Akt signaling.","evidence":"Platelet-specific GRK2 KO, laser thrombosis model, Ca2+/Rap1/Akt assays, Gβγ Co-IP","pmids":["35793439"],"confidence":"High","gaps":["Direct ADP-receptor phosphosites by GRK2 not mapped"]},{"year":2023,"claim":"Provided a high-resolution structural basis for GRK2 receptor engagement and biased agonism, showing the GRK2 N-helix docks into the receptor pocket and SBI-553 clashes with Gαq.","evidence":"Cryo-EM of NTSR1–GRK2–Gαq with SBI-553","pmids":["37532940"],"confidence":"High","gaps":["Conformational transitions during catalysis not captured","Generalizability across receptor classes untested structurally"]},{"year":2023,"claim":"Identified SAV1 as a GRK2 substrate whose phosphorylation drives its degradation, impairing Hippo-YAP and promoting synovial fibroblast proliferation in arthritis.","evidence":"Co-IP, SAV1 ubiquitination, YAP phosphorylation/translocation, CIA rat model","pmids":["38486990"],"confidence":"Medium","gaps":["SAV1 phosphosite(s) and responsible E3 ligase not defined"]},{"year":2024,"claim":"Resolved the ciliary Hedgehog mechanism: GRK2 relocates to the ciliary shaft, phosphorylates SMO, and enables active SMO to bind and inactivate PKA-C, completing the Hh transduction step.","evidence":"Live-cell ciliary imaging, reconstitution, SMO phosphorylation, PKA-C binding, zebrafish/mouse models","pmids":["39138140"],"confidence":"High","gaps":["Trigger for GRK2 ciliary relocalization not fully defined"]},{"year":null,"claim":"How GRK2's many context-specific functions are coordinated—which substrates, scaffolds, and localization cues dominate in a given cell type and how the phosphorylation code on GRK2 itself selects among them—remains unresolved.","evidence":"No single study integrates the receptor, RGS-scaffold, non-receptor substrate, and localization programs","pmids":[],"confidence":"Low","gaps":["No unifying model linking GRK2 regulatory phosphosites to substrate/localization choice","Stoichiometry and competition among partners in vivo unknown","Structural states beyond the receptor-bound complex uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4,6,12,13,15,18,22,25,32,35]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2,10,11,19,17,28]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,14,8,33]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[28,27,37,3]}],"localization":[{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[22,23]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[20]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[13]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[26,34,3]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[4,10]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,28,27,37]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,14,21,22,23]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[7,13]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,33,38]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[25]}],"complexes":[],"partners":["RKIP","HDAC6","PIN1","GNAQ","APC","PTCH1","MALT1","GBG"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25098","full_name":"Beta-adrenergic receptor kinase 1","aliases":["G-protein coupled receptor kinase 2"],"length_aa":689,"mass_kda":79.6,"function":"Specifically phosphorylates the agonist-occupied form of the beta-adrenergic and closely related receptors, probably inducing a desensitization of them (PubMed:19715378). Phosphorylates catecholamine-activated ADRB2 to regulate physiological cardiomyocyte contraction rate responses (By similarity). Also phosphorylates ligand-bound C3a and C5a anaphylatoxin receptors (C3AR1 and C5AR1, respectively), leading to receptor desensitization (PubMed:21799898, PubMed:23077507). Key regulator of LPAR1 signaling (PubMed:19306925). Competes with RALA for binding to LPAR1 thus affecting the signaling properties of the receptor (PubMed:19306925). Desensitizes LPAR1 and LPAR2 in a phosphorylation-independent manner (PubMed:19306925). Positively regulates ciliary smoothened (SMO)-dependent Hedgehog (Hh) signaling pathway by facilitating the trafficking of SMO into the cilium and the stimulation of SMO activity (By similarity). Inhibits relaxation of airway smooth muscle in response to blue light (PubMed:30284927)","subcellular_location":"Cytoplasm; Cell membrane; Postsynapse; Presynapse","url":"https://www.uniprot.org/uniprotkb/P25098/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GRK2","classification":"Not Classified","n_dependent_lines":126,"n_total_lines":1208,"dependency_fraction":0.10430463576158941},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000173020","cell_line_id":"CID001921","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"ADRBK1","stoichiometry":10.0},{"gene":"FOXR1","stoichiometry":0.2},{"gene":"CALCOCO1","stoichiometry":0.2},{"gene":"CDC42BPA","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001921","total_profiled":1310},"omim":[{"mim_id":"617239","title":"MYASTHENIC SYNDROME, CONGENITAL, 21, PRESYNAPTIC; CMS21","url":"https://www.omim.org/entry/617239"},{"mim_id":"608678","title":"INTERLEUKIN 33; IL33","url":"https://www.omim.org/entry/608678"},{"mim_id":"608564","title":"GIT ArfGAP 2; GIT2","url":"https://www.omim.org/entry/608564"},{"mim_id":"608434","title":"GIT ArfGAP 1; GIT1","url":"https://www.omim.org/entry/608434"},{"mim_id":"607228","title":"MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER X2; MRGPRX2","url":"https://www.omim.org/entry/607228"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GRK2"},"hgnc":{"alias_symbol":["BARK1"],"prev_symbol":["ADRBK1"]},"alphafold":{"accession":"P25098","domains":[{"cath_id":"3.30.200.20","chopping":"1-30_184-275_481-514","consensus_level":"medium","plddt":88.4802,"start":1,"end":514},{"cath_id":"1.10.167.10","chopping":"53-168","consensus_level":"high","plddt":93.1734,"start":53,"end":168},{"cath_id":"1.10.510.10","chopping":"283-478","consensus_level":"medium","plddt":94.8284,"start":283,"end":478},{"cath_id":"2.30.29.30","chopping":"560-659","consensus_level":"high","plddt":90.5322,"start":560,"end":659}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25098","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25098-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25098-F1-predicted_aligned_error_v6.png","plddt_mean":89.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GRK2","jax_strain_url":"https://www.jax.org/strain/search?query=GRK2"},"sequence":{"accession":"P25098","fasta_url":"https://rest.uniprot.org/uniprotkb/P25098.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25098/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25098"}},"corpus_meta":[{"pmid":"14654844","id":"PMC_14654844","title":"Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/14654844","citation_count":319,"is_preprint":false},{"pmid":"16055494","id":"PMC_16055494","title":"Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure.","date":"2005","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/16055494","citation_count":161,"is_preprint":false},{"pmid":"10574913","id":"PMC_10574913","title":"Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10574913","citation_count":152,"is_preprint":false},{"pmid":"25739765","id":"PMC_25739765","title":"Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25739765","citation_count":133,"is_preprint":false},{"pmid":"22277298","id":"PMC_22277298","title":"GRK2: multiple roles beyond G protein-coupled receptor desensitization.","date":"2012","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22277298","citation_count":129,"is_preprint":false},{"pmid":"37532940","id":"PMC_37532940","title":"GPCR activation and GRK2 assembly by a biased intracellular agonist.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37532940","citation_count":105,"is_preprint":false},{"pmid":"22193721","id":"PMC_22193721","title":"A novel GRK2/HDAC6 interaction modulates cell spreading and motility.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22193721","citation_count":101,"is_preprint":false},{"pmid":"20147541","id":"PMC_20147541","title":"GRK2: a novel cell-specific regulator of severity and duration of inflammatory pain.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20147541","citation_count":96,"is_preprint":false},{"pmid":"20800067","id":"PMC_20800067","title":"GRK2 as a novel gene therapy target in heart failure.","date":"2010","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/20800067","citation_count":95,"is_preprint":false},{"pmid":"24133451","id":"PMC_24133451","title":"Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy.","date":"2013","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24133451","citation_count":92,"is_preprint":false},{"pmid":"27601479","id":"PMC_27601479","title":"Cardiac Fibroblast GRK2 Deletion Enhances Contractility and Remodeling Following Ischemia/Reperfusion Injury.","date":"2016","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/27601479","citation_count":86,"is_preprint":false},{"pmid":"24231349","id":"PMC_24231349","title":"Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24231349","citation_count":83,"is_preprint":false},{"pmid":"11042191","id":"PMC_11042191","title":"Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11042191","citation_count":80,"is_preprint":false},{"pmid":"30837878","id":"PMC_30837878","title":"G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30837878","citation_count":79,"is_preprint":false},{"pmid":"31432234","id":"PMC_31432234","title":"G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub.","date":"2019","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/31432234","citation_count":76,"is_preprint":false},{"pmid":"15241473","id":"PMC_15241473","title":"GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15241473","citation_count":76,"is_preprint":false},{"pmid":"15284439","id":"PMC_15284439","title":"The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na+ channels.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15284439","citation_count":69,"is_preprint":false},{"pmid":"9678590","id":"PMC_9678590","title":"G protein-coupled receptor kinase 2 (GRK2): mechanisms of regulation and physiological functions.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9678590","citation_count":66,"is_preprint":false},{"pmid":"20080565","id":"PMC_20080565","title":"G protein-coupled receptor kinase 2 (GRK2) modulation and cell cycle progression.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20080565","citation_count":66,"is_preprint":false},{"pmid":"33568523","id":"PMC_33568523","title":"Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis.","date":"2021","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33568523","citation_count":58,"is_preprint":false},{"pmid":"22229578","id":"PMC_22229578","title":"GRK2 inhibition in heart failure: something old, something new.","date":"2012","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/22229578","citation_count":57,"is_preprint":false},{"pmid":"20443852","id":"PMC_20443852","title":"Enhanced GRK2 expression and desensitization of betaAR vasodilatation in hypertensive patients.","date":"2008","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/20443852","citation_count":57,"is_preprint":false},{"pmid":"27720394","id":"PMC_27720394","title":"G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.","date":"2016","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/27720394","citation_count":56,"is_preprint":false},{"pmid":"28594409","id":"PMC_28594409","title":"EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3K-AKT signaling pathway.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28594409","citation_count":55,"is_preprint":false},{"pmid":"7673171","id":"PMC_7673171","title":"The beta-adrenergic receptor kinase (GRK2) is regulated by phospholipids.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7673171","citation_count":54,"is_preprint":false},{"pmid":"28818206","id":"PMC_28818206","title":"Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression.","date":"2017","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28818206","citation_count":53,"is_preprint":false},{"pmid":"21127457","id":"PMC_21127457","title":"Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.","date":"2011","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/21127457","citation_count":50,"is_preprint":false},{"pmid":"26224342","id":"PMC_26224342","title":"Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy.","date":"2015","source":"Journal of cardiovascular translational research","url":"https://pubmed.ncbi.nlm.nih.gov/26224342","citation_count":49,"is_preprint":false},{"pmid":"19502428","id":"PMC_19502428","title":"Kinase activity-independent regulation of cyclin pathway by GRK2 is essential for zebrafish early development.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19502428","citation_count":48,"is_preprint":false},{"pmid":"9716377","id":"PMC_9716377","title":"GTP-binding-protein-coupled receptor kinase 2 (GRK2) binds and phosphorylates tubulin.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9716377","citation_count":46,"is_preprint":false},{"pmid":"29487132","id":"PMC_29487132","title":"The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29487132","citation_count":45,"is_preprint":false},{"pmid":"33060647","id":"PMC_33060647","title":"Dissecting the roles of GRK2 and GRK3 in μ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33060647","citation_count":45,"is_preprint":false},{"pmid":"32096468","id":"PMC_32096468","title":"Agonist-selective recruitment of engineered protein probes and of GRK2 by opioid receptors in living cells.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32096468","citation_count":44,"is_preprint":false},{"pmid":"35132350","id":"PMC_35132350","title":"The ROS/GRK2/HIF-1α/NLRP3 Pathway Mediates Pyroptosis of Fibroblast-Like Synoviocytes and the Regulation of Monomer Derivatives of Paeoniflorin.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35132350","citation_count":44,"is_preprint":false},{"pmid":"33372534","id":"PMC_33372534","title":"Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.","date":"2020","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/33372534","citation_count":44,"is_preprint":false},{"pmid":"22796071","id":"PMC_22796071","title":"Transient decrease in nociceptor GRK2 expression produces long-term enhancement in inflammatory pain.","date":"2012","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22796071","citation_count":43,"is_preprint":false},{"pmid":"29166798","id":"PMC_29166798","title":"GRK2 as a therapeutic target for heart failure.","date":"2017","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/29166798","citation_count":42,"is_preprint":false},{"pmid":"30538174","id":"PMC_30538174","title":"Restricting mitochondrial GRK2 post-ischemia confers cardioprotection by reducing myocyte death and maintaining glucose oxidation.","date":"2018","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/30538174","citation_count":42,"is_preprint":false},{"pmid":"26120872","id":"PMC_26120872","title":"G Protein-Coupled Receptor Kinase 2 (GRK2) and 5 (GRK5) Exhibit Selective Phosphorylation of the Neurotensin Receptor in Vitro.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26120872","citation_count":42,"is_preprint":false},{"pmid":"27113758","id":"PMC_27113758","title":"An essential role for Grk2 in Hedgehog signalling downstream of Smoothened.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/27113758","citation_count":41,"is_preprint":false},{"pmid":"28389415","id":"PMC_28389415","title":"G protein-coupled receptor kinase 2 (GRK2) as an integrative signalling node in the regulation of cardiovascular function and metabolic homeostasis.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28389415","citation_count":38,"is_preprint":false},{"pmid":"30915659","id":"PMC_30915659","title":"Calpains mediate isoproterenol-induced hypertrophy through modulation of GRK2.","date":"2019","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30915659","citation_count":38,"is_preprint":false},{"pmid":"36698265","id":"PMC_36698265","title":"Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine-Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36698265","citation_count":38,"is_preprint":false},{"pmid":"26936374","id":"PMC_26936374","title":"GRK2 overexpression inhibits IGF1-induced proliferation and migration of human hepatocellular carcinoma cells by downregulating EGR1.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26936374","citation_count":38,"is_preprint":false},{"pmid":"8885248","id":"PMC_8885248","title":"GRK2 and beta-arrestin 1 as negative regulators of thyrotropin receptor-stimulated response.","date":"1996","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8885248","citation_count":37,"is_preprint":false},{"pmid":"31967309","id":"PMC_31967309","title":"CP-25 inhibits PGE2-induced angiogenesis by down-regulating EP4/AC/cAMP/PKA-mediated GRK2 translocation.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31967309","citation_count":34,"is_preprint":false},{"pmid":"19338266","id":"PMC_19338266","title":"GRK2 activation by receptors: role of the kinase large lobe and carboxyl-terminal tail.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19338266","citation_count":33,"is_preprint":false},{"pmid":"19372742","id":"PMC_19372742","title":"New roles of G protein-coupled receptor kinase 2 (GRK2) in cell migration.","date":"2009","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/19372742","citation_count":31,"is_preprint":false},{"pmid":"19932746","id":"PMC_19932746","title":"Cell-specific roles of GRK2 in onset and severity of hypoxic-ischemic brain damage in neonatal mice.","date":"2009","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19932746","citation_count":30,"is_preprint":false},{"pmid":"25460042","id":"PMC_25460042","title":"Insulin induces IRS2-dependent and GRK2-mediated β2AR internalization to attenuate βAR signaling in cardiomyocytes.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25460042","citation_count":30,"is_preprint":false},{"pmid":"27568556","id":"PMC_27568556","title":"GRK2 Constitutively Governs Peripheral Delta Opioid Receptor Activity.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27568556","citation_count":29,"is_preprint":false},{"pmid":"32326036","id":"PMC_32326036","title":"Antagonistic Roles of GRK2 and GRK5 in Cardiac Aldosterone Signaling Reveal GRK5-Mediated Cardioprotection via Mineralocorticoid Receptor Inhibition.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32326036","citation_count":29,"is_preprint":false},{"pmid":"31594751","id":"PMC_31594751","title":"Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31594751","citation_count":28,"is_preprint":false},{"pmid":"24702056","id":"PMC_24702056","title":"GRK2 in the heart: a GPCR kinase and beyond.","date":"2014","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24702056","citation_count":27,"is_preprint":false},{"pmid":"25147759","id":"PMC_25147759","title":"Trafficking GRK2: Cellular and Metabolic consequences of GRK2 subcellular localization.","date":"2014","source":"Translational medicine @ UniSa","url":"https://pubmed.ncbi.nlm.nih.gov/25147759","citation_count":27,"is_preprint":false},{"pmid":"34652301","id":"PMC_34652301","title":"Spinal Neuronal GRK2 Contributes to Preventive Effect by Electroacupuncture on Cisplatin-Induced Peripheral Neuropathy in Mice.","date":"2022","source":"Anesthesia and analgesia","url":"https://pubmed.ncbi.nlm.nih.gov/34652301","citation_count":27,"is_preprint":false},{"pmid":"21615207","id":"PMC_21615207","title":"G Protein-coupled receptor kinase 2 (GRK2): A novel modulator of insulin resistance.","date":"2011","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21615207","citation_count":26,"is_preprint":false},{"pmid":"38261818","id":"PMC_38261818","title":"GRK2 inhibits Flt-1+ macrophage infiltration and its proangiogenic properties in rheumatoid arthritis.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/38261818","citation_count":26,"is_preprint":false},{"pmid":"16725308","id":"PMC_16725308","title":"Tyrosine phosphorylation of G-protein-coupled-receptor kinase 2 (GRK2) by c-Src modulates its interaction with Galphaq.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16725308","citation_count":26,"is_preprint":false},{"pmid":"35115050","id":"PMC_35115050","title":"Neuronal GRK2 regulates microglial activation and contributes to electroacupuncture analgesia on inflammatory pain in mice.","date":"2022","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/35115050","citation_count":26,"is_preprint":false},{"pmid":"35878706","id":"PMC_35878706","title":"GRK2 in cardiovascular disease and its potential as a therapeutic target.","date":"2022","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/35878706","citation_count":25,"is_preprint":false},{"pmid":"30934608","id":"PMC_30934608","title":"Antidiabetic and Cardioprotective Effects of Pharmacological Inhibition of GRK2 in db/db Mice.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30934608","citation_count":25,"is_preprint":false},{"pmid":"17544362","id":"PMC_17544362","title":"GRK2 interacts with and phosphorylates Nedd4 and Nedd4-2.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17544362","citation_count":25,"is_preprint":false},{"pmid":"33200460","id":"PMC_33200460","title":"Mutations in GRK2 cause Jeune syndrome by impairing Hedgehog and canonical Wnt signaling.","date":"2020","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33200460","citation_count":25,"is_preprint":false},{"pmid":"22336718","id":"PMC_22336718","title":"Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.","date":"2012","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22336718","citation_count":25,"is_preprint":false},{"pmid":"19556343","id":"PMC_19556343","title":"Inhibition of WNT signaling by G protein-coupled receptor (GPCR) kinase 2 (GRK2).","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19556343","citation_count":25,"is_preprint":false},{"pmid":"16963227","id":"PMC_16963227","title":"Hydrogen peroxide impairs GRK2 translation via a calpain-dependent and cdk1-mediated pathway.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16963227","citation_count":24,"is_preprint":false},{"pmid":"25561731","id":"PMC_25561731","title":"GRK2 targeted knock-down results in spontaneous hypertension, and altered vascular GPCR signaling.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25561731","citation_count":23,"is_preprint":false},{"pmid":"30701991","id":"PMC_30701991","title":"GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy.","date":"2019","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/30701991","citation_count":22,"is_preprint":false},{"pmid":"28130200","id":"PMC_28130200","title":"Targeting GPCR-Gβγ-GRK2 signaling as a novel strategy for treating cardiorenal pathologies.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28130200","citation_count":22,"is_preprint":false},{"pmid":"18437630","id":"PMC_18437630","title":"GRK2-dependent desensitization downstream of G proteins.","date":"2008","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/18437630","citation_count":22,"is_preprint":false},{"pmid":"33467677","id":"PMC_33467677","title":"The Metabolic Role of GRK2 in Insulin Resistance and Associated Conditions.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33467677","citation_count":22,"is_preprint":false},{"pmid":"28077324","id":"PMC_28077324","title":"GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28077324","citation_count":22,"is_preprint":false},{"pmid":"28814745","id":"PMC_28814745","title":"Suppression of GRK2 expression reduces endothelial dysfunction by restoring glucose homeostasis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28814745","citation_count":22,"is_preprint":false},{"pmid":"32234810","id":"PMC_32234810","title":"A New Paroxetine-Based GRK2 Inhibitor Reduces Internalization of the μ-Opioid Receptor.","date":"2020","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32234810","citation_count":22,"is_preprint":false},{"pmid":"25483406","id":"PMC_25483406","title":"Regulatory SNPs and transcriptional factor binding sites in ADRBK1, AKT3, ATF3, DIO2, TBXA2R and VEGFA.","date":"2014","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/25483406","citation_count":21,"is_preprint":false},{"pmid":"30952428","id":"PMC_30952428","title":"High-glucose induces cardiac myocytes apoptosis through Foxo1 /GRK2 signaling pathway.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30952428","citation_count":21,"is_preprint":false},{"pmid":"23460259","id":"PMC_23460259","title":"GRK2 negatively regulates IGF-1R signaling pathway and cyclins' expression in HepG2 cells.","date":"2013","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23460259","citation_count":21,"is_preprint":false},{"pmid":"35065240","id":"PMC_35065240","title":"Lycium barbarum polysaccharide antagonizes cardiomyocyte apoptosis by inhibiting the upregulation of GRK2 induced by I/R injury, and salvage mitochondrial fission/fusion imbalance and AKT/eNOS signaling.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35065240","citation_count":21,"is_preprint":false},{"pmid":"27362616","id":"PMC_27362616","title":"G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives.","date":"2016","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27362616","citation_count":20,"is_preprint":false},{"pmid":"27573285","id":"PMC_27573285","title":"Regulatory effects of GRK2 on GPCRs and non-GPCRs and possible use as a drug target (Review).","date":"2016","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27573285","citation_count":20,"is_preprint":false},{"pmid":"27862165","id":"PMC_27862165","title":"GRK2/β-arrestin mediates arginine vasopressin-induced cardiac fibroblast proliferation.","date":"2017","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27862165","citation_count":20,"is_preprint":false},{"pmid":"30946029","id":"PMC_30946029","title":"Alteration of myocardial GRK2 produces a global metabolic phenotype.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30946029","citation_count":19,"is_preprint":false},{"pmid":"39138140","id":"PMC_39138140","title":"GRK2 kinases in the primary cilium initiate SMOOTHENED-PKA signaling in the Hedgehog cascade.","date":"2024","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/39138140","citation_count":18,"is_preprint":false},{"pmid":"18618354","id":"PMC_18618354","title":"G protein-coupled receptor kinase 2 (GRK2) in migration and inflammation.","date":"2008","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18618354","citation_count":18,"is_preprint":false},{"pmid":"23904266","id":"PMC_23904266","title":"G protein-coupled receptor kinase 2 (GRK2) is localized to centrosomes and mediates epidermal growth factor-promoted centrosomal separation.","date":"2013","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23904266","citation_count":18,"is_preprint":false},{"pmid":"24776686","id":"PMC_24776686","title":"Selective deletion of GRK2 alters psychostimulant-induced behaviors and dopamine neurotransmission.","date":"2014","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24776686","citation_count":17,"is_preprint":false},{"pmid":"22254193","id":"PMC_22254193","title":"GRK2 and β-arrestins in cardiovascular disease: Something old, something new.","date":"2011","source":"American journal of cardiovascular disease","url":"https://pubmed.ncbi.nlm.nih.gov/22254193","citation_count":17,"is_preprint":false},{"pmid":"35430346","id":"PMC_35430346","title":"Double life: How GRK2 and β-arrestin signaling participate in diseases.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35430346","citation_count":16,"is_preprint":false},{"pmid":"31554835","id":"PMC_31554835","title":"GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31554835","citation_count":16,"is_preprint":false},{"pmid":"28213524","id":"PMC_28213524","title":"G protein-coupled receptor kinase-2 (GRK-2) regulates serotonin metabolism through the monoamine oxidase AMX-2 in Caenorhabditis elegans.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28213524","citation_count":16,"is_preprint":false},{"pmid":"38486990","id":"PMC_38486990","title":"GRK2 mediated degradation of SAV1 initiates hyperplasia of fibroblast-like synoviocytes in rheumatoid arthritis.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/38486990","citation_count":15,"is_preprint":false},{"pmid":"30061705","id":"PMC_30061705","title":"GRK2 knockdown in mice exacerbates kidney injury and alters renal mechanisms of blood pressure regulation.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30061705","citation_count":15,"is_preprint":false},{"pmid":"29922165","id":"PMC_29922165","title":"Low GRK2 Underlies Hyperalgesic Priming by Glial Cell-Derived Neurotrophic Factor.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29922165","citation_count":15,"is_preprint":false},{"pmid":"35793439","id":"PMC_35793439","title":"GRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35793439","citation_count":14,"is_preprint":false},{"pmid":"31961340","id":"PMC_31961340","title":"GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31961340","citation_count":14,"is_preprint":false},{"pmid":"36461590","id":"PMC_36461590","title":"Targeted inhibition of the GRK2/HIF-1α pathway is an effective strategy to alleviate synovial hypoxia and inflammation.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36461590","citation_count":14,"is_preprint":false},{"pmid":"24376730","id":"PMC_24376730","title":"Co-expression of GRK2 reveals a novel conformational state of the µ-opioid receptor.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376730","citation_count":14,"is_preprint":false},{"pmid":"32413989","id":"PMC_32413989","title":"GRK2-Dependent HuR Phosphorylation Regulates HIF1α Activation under Hypoxia or Adrenergic Stress.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32413989","citation_count":14,"is_preprint":false},{"pmid":"26279567","id":"PMC_26279567","title":"GRK2 Fine-Tunes Circadian Clock Speed and Entrainment via Transcriptional and Post-translational Control of PERIOD Proteins.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26279567","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49793,"output_tokens":10113,"usd":0.150537,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20507,"output_tokens":10383,"usd":0.181055,"stage2_stop_reason":"end_turn"},"total_usd":0.331592,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"RKIP (Raf kinase inhibitor protein) is a physiological inhibitor of GRK2. After GPCR stimulation, PKC phosphorylates RKIP at Ser153, causing RKIP to dissociate from Raf-1 and associate with GRK2, blocking GRK2 activity and inhibiting receptor internalization.\",\n      \"method\": \"Co-immunoprecipitation, PKC phosphorylation assay, cardiomyocyte functional studies, RKIP knockdown\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, phosphorylation site identified, functional validation in cardiomyocytes, multiple orthogonal methods\",\n      \"pmids\": [\"14654844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ERK1/2 phosphorylates GRK2 at Ser670, a C-terminal residue in an ERK consensus sequence, impairing GRK2 ability to phosphorylate both soluble and membrane-incorporated receptor substrates and dramatically attenuating Gβγ-mediated activation of GRK2.\",\n      \"method\": \"Mass spectrometry, mutational analysis, in vitro ERK1 phosphorylation assay, HEK293 cell kinase activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, mass spectrometry site identification, mutagenesis, and cell-based validation with multiple orthogonal methods\",\n      \"pmids\": [\"10574913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PKC phosphorylates GRK2 at Ser29, located in the calmodulin-binding region. Calmodulin tonically inhibits GRK2, and PKC-mediated phosphorylation at Ser29 abolishes calmodulin inhibition of GRK2 kinase activity.\",\n      \"method\": \"In vitro PKC phosphorylation assay, 2D peptide mapping, HPLC-MS site identification, S29A mutagenesis, HEK293 cell transfection, calmodulin binding/inhibition assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, MS-based site identification, mutagenesis, and cell-based validation in single rigorous study\",\n      \"pmids\": [\"11042191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of the NTSR1–GRK2–Gαq complex with arrestin-biased ligand SBI-553 reveals that the N-terminal helix of GRK2 docks into the open cytoplasmic pocket of the receptor (analogous to G protein binding). SBI-553 binds at the GRK2–NTSR1 interface to enhance GRK2 binding while clashing with Gαq binding, providing a structural basis for arrestin-biased signaling.\",\n      \"method\": \"Cryo-EM structure determination\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structure with functional interpretation, single rigorous study\",\n      \"pmids\": [\"37532940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GRK2 directly associates with and phosphorylates HDAC6, stimulating its α-tubulin deacetylase activity. Phosphorylation of GRK2 at S670 specifically potentiates this interaction. GRK2 and HDAC6 co-localize in lamellipodia of migrating cells, promoting local tubulin deacetylation and enhanced cell motility.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site mutagenesis (K220R, S670A), live-cell imaging, migration assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vitro phosphorylation, mutagenesis, localization with functional consequence, multiple orthogonal methods\",\n      \"pmids\": [\"22193721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"GRK2 functions as a negative regulator of insulin-stimulated GLUT4 translocation via its RGS domain, which sequesters activated Gαq/11. A GRK2 mutant lacking the RGS domain has no effect on insulin-stimulated glucose transport.\",\n      \"method\": \"Microinjection of anti-GRK2 antibody, siRNA knockdown, adenovirus-mediated overexpression of wild-type and kinase-deficient GRK2, RGS domain deletion mutant, 2-deoxyglucose uptake assay, GLUT4 translocation assay in 3T3-L1 adipocytes\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal loss-of-function and gain-of-function approaches with domain-specific mutant establishing mechanism\",\n      \"pmids\": [\"15241473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"GRK2 phosphorylates the C-terminus of the ENaC β-subunit, rendering ENaC channels insensitive to inhibition by the ubiquitin ligase Nedd4-2, thereby maintaining channels in the active state.\",\n      \"method\": \"Electrophysiology (Xenopus oocyte expression), in vitro kinase assay, co-expression studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation assay and functional electrophysiology readout in single study\",\n      \"pmids\": [\"15284439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK2 protein levels are transiently down-regulated during G2/M transition via CDK2-mediated phosphorylation of GRK2 at Ser670, which triggers binding to the prolyl-isomerase Pin1 and subsequent proteasomal degradation. Prevention of this phosphorylation markedly delays cell cycle progression.\",\n      \"method\": \"Cell synchronization assays, CDK2 in vitro phosphorylation, S670A mutagenesis, Pin1 co-immunoprecipitation, flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro phosphorylation, Co-IP, mutagenesis, and cell cycle analysis with multiple orthogonal methods\",\n      \"pmids\": [\"20080565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK2 interacts with PTCH1 (patched homolog 1) at residues 262-379, reducing PTCH1 association with cyclin B1 and disrupting PTCH1-mediated inhibition of cyclin B1 nuclear translocation. This function is kinase activity-independent and is required for normal zebrafish early embryonic development.\",\n      \"method\": \"Zebrafish GRK2 morpholino knockdown, rescue with kinase-dead K220R mutant, co-immunoprecipitation, deletion mutagenesis, cell cycle and proliferation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo rescue experiments, Co-IP, domain mapping, cell cycle assays, multiple orthogonal methods\",\n      \"pmids\": [\"19502428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"c-Src phosphorylates GRK2 on tyrosine residues (Y13, Y86, Y92) in the RGS-homology region, which increases GRK2 interaction with Gαq and enhances inhibition of the Gαq/phospholipase Cβ signaling pathway.\",\n      \"method\": \"Co-immunoprecipitation, tyrosine phosphorylation site mutagenesis (Y13,86,92F), phosphomimetic mutant, M1 muscarinic receptor stimulation assay, PLC-β signaling assay in cells\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and mutagenesis in single lab, functional signaling readout\",\n      \"pmids\": [\"16725308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"GRK2 directly binds tubulin via its C-terminal domain (residues 467-689) and phosphorylates tubulin (Km ~3 µM, 1.3 mol phosphate/dimer). Tubulin and Gβγ bind GRK2 independently. GRK2-mediated tubulin phosphorylation is stimulated by Gβγ and agonist-activated muscarinic receptors.\",\n      \"method\": \"GST pulldown, co-purification via tubulin polymerization-depolymerization, in vitro kinase assay, Western blot\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution with direct kinase assay and pulldown, single lab\",\n      \"pmids\": [\"9716377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GRK2 requires acidic phospholipids for phosphorylation of the β2-adrenergic receptor; phospholipids increase catalytic activity via a conformational change in the kinase without altering Km for peptide substrate. PIP2 inhibits GRK2 activity and reduces crosslinker incorporation.\",\n      \"method\": \"Mixed micelle phosphorylation assay, photoaffinity crosslinking with [125I]ACTP, Km determination, proteolytic mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mechanistic crosslinking and kinetics, single lab\",\n      \"pmids\": [\"7673171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK2 directly phosphorylates p38 MAPK at Thr123, a residue at the entrance of a docking groove. The phosphomimetic T123E mutant of p38 shows reduced binding to MKK6 and impaired p38 activation, and elevated GRK2 levels downregulate p38-dependent cellular responses.\",\n      \"method\": \"In vitro kinase assay, phosphomimetic mutagenesis (T123E), MKK6 co-immunoprecipitation, substrate phosphorylation assays (MEF2, MK2, ATF2), macrophage cytokine assay in GRK2+/- mice\",\n      \"journal\": \"Journal of receptor and signal transduction research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phosphorylation, mutagenesis, and Co-IP; in vivo validation with GRK2+/- mice; single lab\",\n      \"pmids\": [\"18437630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK2 localizes to centrosomes and, upon EGF stimulation, directly phosphorylates and activates the kinase Mst2, which drives EGFR-mediated centrosome separation in a Nek2A-dependent manner.\",\n      \"method\": \"Immunofluorescence localization, GRK2 knockdown, in vitro kinase assay (GRK2 phosphorylation of Mst2), dominant-negative Mst2, centrosome separation assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro phosphorylation, localization with functional consequence, dominant-negative validation; single lab\",\n      \"pmids\": [\"23904266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK2 negatively regulates WNT/β-catenin (canonical Wnt) signaling by binding APC via its RGS domain. GRK2 enzymatic activity is required for the GRK2-APC interaction and for inhibition of β-catenin stabilization and nuclear translocation. RGS domain deletion abolishes both the APC interaction and inhibition of Wnt signaling.\",\n      \"method\": \"Reporter assay (Wnt-responsive luciferase), co-immunoprecipitation, siRNA knockdown of endogenous GRK2, RGS domain deletion mutant, β-catenin immunofluorescence in calvarial osteoblasts\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping, siRNA, functional reporter assay; single lab\",\n      \"pmids\": [\"19556343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GRK2 selectively phosphorylates only C-terminal Ser residues of agonist-activated neurotensin receptor 1 (NTSR1) in nanodiscs, in an agonist-dependent manner. Negatively charged lipids in the vicinity of NTSR1 directly affect the extent of GRK2-mediated phosphorylation. GRK2 does not require acidic residues upstream of phospho-acceptors for NTSR1 (unlike β2AR and μOR).\",\n      \"method\": \"In vitro phosphorylation in nanodiscs, mass spectrometry phosphosite mapping, NTSR1 mutational analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in nanodiscs with MS-based phosphosite mapping and mutagenesis; single rigorous study\",\n      \"pmids\": [\"26120872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GRK2 promotes breast cancer progression via phosphorylation and activation of HDAC6, which deacetylates Pin1, enhancing Pin1 stability and its interactions with mitotic regulators. This GRK2/HDAC6/Pin1 axis promotes proliferation and anchorage-independent growth.\",\n      \"method\": \"Co-immunoprecipitation, GRK2 knockdown/overexpression, in vitro HDAC6 phosphorylation, Pin1 acetylation assay, tumor xenograft in mice\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, in vitro phosphorylation, in vivo xenograft, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"27720394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Insulin stimulates GRK2 recruitment to β2AR via an IRS2-dependent mechanism. GRK2 phosphorylates β2AR at GRK sites Ser355/356, promoting β2AR internalization and suppressing βAR-induced cAMP-PKA signaling and contractile response in cardiomyocytes.\",\n      \"method\": \"Co-immunoprecipitation, β2AR phosphorylation assay, β2AR internalization assay, cAMP assay, IRS2 knockout mouse cardiomyocytes, contractility measurement\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, site-specific phosphorylation, receptor internalization, genetic KO; single lab\",\n      \"pmids\": [\"25460042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GRK2 directly interacts with and phosphorylates both Nedd4 and Nedd4-2 at multiple sites, including Thr466 in Nedd4 located in the ww3 domain region that binds ENaC, providing a mechanism for GRK2 regulation of sodium transport.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site identification\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phosphorylation and Co-IP; single lab, limited follow-up\",\n      \"pmids\": [\"17544362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GRK2 activation by receptor requires residues in the C-tail region of the kinase, particularly Val477. The V477D mutant shows a 12-fold lower kcat with no change in Km, indicating a defect in acquiring the closed (active) kinase conformation, and is resistant to activation by agonist-bound β2AR.\",\n      \"method\": \"Site-directed mutagenesis, in vitro kinase assay with Michaelis-Menten kinetics, rhodopsin and β2AR phosphorylation assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with kinetic analysis and structure-guided mutagenesis; single lab\",\n      \"pmids\": [\"19338266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GRK2 phosphorylation at Ser670 is required for GRK2 translocation to mitochondria post-ischemia-reperfusion injury. Mice with S670A knock-in show reduced cardiomyocyte death and better cardiac function post-IR, and cultured S670A cardiomyocytes maintain pyruvate dehydrogenase activity and glucose oxidation after IR.\",\n      \"method\": \"S670A knock-in mice, cardiac IR model, cardiomyocyte death assay, mitochondrial respiration assay, pyruvate dehydrogenase activity measurement\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse model, mechanistic biochemical assays, multiple readouts in single rigorous study\",\n      \"pmids\": [\"30538174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"An essential role for GRK2 kinase activity in Hedgehog signaling downstream of Smoothened (Smo) is established in zebrafish; grk2-null embryos are unresponsive to Shh and oncogenic Smo but remain responsive to PKA inhibition.\",\n      \"method\": \"Zebrafish grk2 loss-of-function mutants, kinase-dead rescue experiments, Smo phosphomimetic and phospho-null mutant analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic epistasis in zebrafish with kinase-dead rescue; single lab\",\n      \"pmids\": [\"27113758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GRK2 relocates from the ciliary base to the ciliary shaft upon Smoothened activation, phosphorylates SMO, and enables active SMO to directly bind and inactivate the PKA catalytic subunit, initiating downstream Hedgehog signal transduction.\",\n      \"method\": \"Live-cell imaging of GRK2 relocalization in primary cilia, reconstitution studies, SMO phosphorylation assay, PKA-C binding assay, in vivo zebrafish and mouse models\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reconstitution, localization with functional consequence, in vivo validation in two organisms, multiple orthogonal methods\",\n      \"pmids\": [\"39138140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss-of-function mutations in GRK2 (ADRBK1) cause Jeune syndrome (asphyxiating thoracic dystrophy) by impairing cilia-based Hedgehog signaling and canonical Wnt signaling, specifically through failure to phosphorylate the Wnt co-receptor LRP6.\",\n      \"method\": \"Patient-derived GRK2 null cells, chondrocyte differentiation assay, Hedgehog pathway reporter, canonical Wnt reporter, LRP6 phosphorylation assay\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived cells, pathway reporter assays, phosphorylation assay; single lab\",\n      \"pmids\": [\"33200460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GRK2 interacts with and phosphorylates monoamine oxidase AMX-2 in C. elegans, promoting its function. Loss of grk-2 leads to elevated AMX-2 and increased serotonin metabolism (5-HT→5-HIAA), causing egg-laying defects that are rescued by wild-type but not catalytically inactive GRK-2.\",\n      \"method\": \"C. elegans grk-2 loss-of-function genetics, serotonin/5-HIAA metabolite measurements, co-immunoprecipitation, GRK-2 phosphorylation of AMX-2, cell-specific rescue experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, in vitro phosphorylation, genetic rescue with kinase-dead control; single lab in C. elegans ortholog\",\n      \"pmids\": [\"28213524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GRK2 suppresses transcription of the mPeriod1 gene and physically interacts with PERIOD1 and PERIOD2 proteins to promote PERIOD2 phosphorylation at Ser545, impeding PERIOD1/2 nuclear trafficking and modulating circadian clock period and amplitude.\",\n      \"method\": \"Grk2-deficient mouse behavioral rhythms, SCN electrophysiology, GRK2 Co-IP with PER1/2, in vitro phosphorylation (Ser545), transcriptional reporter assay, nuclear trafficking assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, in vitro phosphorylation site mapping, in vivo Grk2 KO phenotype, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"26279567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK2 is found to naively associate with plasma membrane delta opioid receptor (DOR) in peripheral sensory neurons, inhibiting Gβ subunit association and reducing DOR activity. Bradykinin-activated PKC phosphorylates RKIP, sequestering GRK2 away from DOR onto RKIP, restoring DOR functionality.\",\n      \"method\": \"Co-immunoprecipitation in sensory neurons, DOR functional assay, PKC inhibition, RKIP phosphorylation assay, GRK2-RKIP pulldown\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, functional receptor assay, pharmacological dissection; single lab\",\n      \"pmids\": [\"27568556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The dopamine D2 receptor (D2R) can directly recruit GRK2 in a G protein-independent manner. Using βarr-preferring D2R mutants and the biased ligand UNC9994, direct GRK2 recruitment was shown to drive β-arrestin pathway activation without G protein activation.\",\n      \"method\": \"BRET-based recruitment assay, biased D2R mutants (G protein-preferring and βarr-preferring), pharmacological G protein blockade, βarr2 recruitment assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BRET assay with multiple engineered receptor and ligand tools; single lab\",\n      \"pmids\": [\"29487132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK2 and GRK3 are the primary kinases required for μ-opioid receptor (μ-OR) internalization and β-arrestin2 recruitment in HEK293 cells; GRK2 is more important than GRK3 for these processes. A GRK2/3-independent component of sustained β-arrestin2 plasma membrane recruitment also exists.\",\n      \"method\": \"CRISPR/Cas9 GRK2, GRK3, and GRK2/3 double knockout HEK293 cells, μ-OR internalization assay, β-arrestin2 recruitment assay, rescue expression, CMPD101 pharmacological inhibition\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO, rescue experiments, and pharmacological cross-validation; multiple orthogonal methods\",\n      \"pmids\": [\"33060647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GRK2 is degraded at early ischemia-reperfusion via proteasome (during ischemia) and calpain (during reperfusion) following successive phosphorylation at specific sites. Preventing this degradation with calpain and proteasome inhibitors preserves AKT pathway activity and reduces I/R injury.\",\n      \"method\": \"Isolated rat and porcine heart I/R models, immunoblotting for GRK2 protein, proteasome and calpain inhibitor treatment, Pin1/AKT pathway analysis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two animal model systems, pharmacological intervention with mechanistic readout; single lab\",\n      \"pmids\": [\"31594751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Calpain activation by isoproterenol increases GRK2 protein levels by degrading GRK2's ubiquitin ligase MDM2 (stabilizing GRK2) and by enhancing NF-κB-dependent GRK2 transcription via IκB proteolysis. Genetic downregulation of GRK2 prevents isoproterenol-mediated hypertrophy independently of calpain inhibition.\",\n      \"method\": \"Calpain inhibitor (SNJ-1945) in rats and GRK2 hemizygous mice, MDM2 protein assay, NF-κB/IκB western blot, GRK2 mRNA quantification, cardiac hypertrophy morphological/biochemical markers\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological approaches, mechanistic pathway dissection; single lab\",\n      \"pmids\": [\"30915659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK5 phosphorylates and inhibits the mineralocorticoid receptor (MR) in cardiomyocytes following β2AR activation, suppressing aldosterone-induced MR transcriptional activity, whereas GRK2 phosphorylates and desensitizes GPER (G protein-coupled estrogen receptor).\",\n      \"method\": \"CRISPR/Cas9 GRK5 deletion in H9c2 cells, Co-IP of GRK5-MR, MR transcriptional reporter assay, GRK2 pharmacological inhibition, adult rat ventricular myocyte studies\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO, Co-IP, transcriptional reporter, functional cell biology; single lab\",\n      \"pmids\": [\"32326036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK2 phosphorylates the mRNA-binding protein HuR, increasing HuR cytoplasmic shuttling and HuR binding to HIF-1α mRNA under hypoxia. GRK2-phosphodefective HuR mutants show defective cytosolic accumulation and lower HIF-1α mRNA binding.\",\n      \"method\": \"GRK2 in vitro phosphorylation of HuR, phosphodefective HuR mutagenesis, RIP assay (RNA immunoprecipitation) for HIF-1α mRNA, subcellular fractionation, VEGF-C assay\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phosphorylation, mutagenesis, RNA IP with functional readout; single lab\",\n      \"pmids\": [\"32413989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRK2 binds the death domain of MALT1 and inhibits both MALT1 scaffolding and proteolytic activities, suppressing NF-κB activation downstream of antigen receptor signaling. Lower GRK2 levels in ABC-DLBCL are associated with enhanced tumor growth in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation of GRK2-MALT1, MALT1 protease activity assay, NF-κB reporter assay, GRK2 knockdown, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping, functional protease assay, in vivo tumor model; single lab\",\n      \"pmids\": [\"31961340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12 receptors; platelet-specific GRK2 deletion increases ADP-stimulated Ca2+ mobilization, Rap1 activation, Akt phosphorylation, integrin activation, and impairs ADP receptor desensitization. GRK2 also binds endogenous Gβγ subunits during platelet activation.\",\n      \"method\": \"Platelet-specific GRK2 knockout mice, laser-induced thrombosis model, platelet aggregation assay, Ca2+ mobilization assay, Rap1 activation assay, Akt phosphorylation, cAMP assay, Co-IP of GRK2-Gβγ\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, in vivo thrombosis model, multiple biochemical readouts, Gβγ Co-IP; multiple orthogonal methods\",\n      \"pmids\": [\"35793439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GRK2 phosphorylates SAV1 (Salvador homolog-1), leading to SAV1 ubiquitination and degradation; this impairs Hippo-YAP pathway activity by reducing YAP phosphorylation, promoting YAP nuclear translocation and FLS proliferation in rheumatoid arthritis.\",\n      \"method\": \"GRK2 knockdown/overexpression, Co-immunoprecipitation of GRK2-SAV1, SAV1 ubiquitination assay, YAP phosphorylation and nuclear translocation assay, CIA rat model with paroxetine treatment\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, functional pathway readout, in vivo model; single lab\",\n      \"pmids\": [\"38486990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"EIF3d stabilizes GRK2 protein by blocking ubiquitin-mediated GRK2 degradation, thereby activating PI3K/Akt signaling and promoting gallbladder cancer cell proliferation and migration.\",\n      \"method\": \"Co-immunoprecipitation of EIF3d-GRK2, ubiquitination assay, GRK2 protein stability assay, PI3K/Akt signaling western blot, EIF3d knockdown/overexpression, in vitro and in vivo cancer assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, protein stability and signaling readouts; single lab\",\n      \"pmids\": [\"28594409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GRK2 together with β-arrestin1 desensitizes the TSH receptor: co-transfection of GRK2 and/or β-arrestin1 reduces TSH-induced cAMP accumulation by 35-45% and blunts TSH-stimulated mitogenic activity in thyroid cells.\",\n      \"method\": \"COS7 cell co-transfection with TSH receptor + GRK2 ± β-arrestin1, cAMP accumulation assay, FRTL5 cell line stably overexpressing β-arrestin1, proliferation assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-transfection functional assay and stable cell line; single lab\",\n      \"pmids\": [\"8885248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Reduced GRK2 specifically in microglia/monocytes is required and sufficient to transform acute carrageenan- or CCL3-induced hyperalgesia into chronic hyperalgesia, associated with ongoing microglial activation and increased phospho-p38 and TNF-α in the spinal cord. Separate reduction of GRK2 in Nav1.8 nociceptors increases but does not prolong hyperalgesia, and enhances CCL3-induced TRPV1 sensitization.\",\n      \"method\": \"Cre-Lox cell-specific GRK2 knockdown (LysM-Cre for microglia, Nav1.8-Cre for nociceptors), carrageenan/CCL3 hyperalgesia models, intrathecal p38/TNF-α/minocycline inhibition, TRPV1 sensitization assay\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-specific conditional KO, genetic epistasis, pharmacological pathway validation; multiple orthogonal methods\",\n      \"pmids\": [\"20147541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Reduced nociceptor GRK2 promotes cAMP signaling to EPAC1, and the balance between GRK2 and EPAC1 levels determines whether acute hyperalgesia transitions to chronic pain. Viral gene transfer to increase GRK2 or EPAC1 heterozygosity prevents chronic PGE2-induced hyperalgesia in two priming models.\",\n      \"method\": \"Viral (HSV) GRK2 gene transfer, Epac1 heterozygous and antisense-ODN mice, two hyperalgesic priming models (carrageenan and ΨεRACK), CFA chronic pain model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — viral gene transfer, genetic mouse models, pharmacological validation; multiple orthogonal methods replicated in two priming models\",\n      \"pmids\": [\"24231349\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GRK2 is a multifunctional serine/threonine kinase that canonically phosphorylates agonist-occupied GPCRs to initiate β-arrestin recruitment, receptor uncoupling, and internalization; its activity and localization are tightly regulated by phosphorylation (PKC at Ser29 relieving calmodulin inhibition; ERK/CDK2 at Ser670 promoting Pin1 binding and degradation or mitochondrial translocation; c-Src on tyrosines enhancing Gαq binding), by lipid cofactors and Gβγ; and by interacting proteins (RKIP, calmodulin). Beyond GPCR desensitization, GRK2 directly phosphorylates non-receptor substrates including HDAC6 (regulating tubulin deacetylation and cell motility), p38 MAPK, Mst2, tubulin, ENaC β-subunit, Nedd4/Nedd4-2, HuR, SAV1, and PERIOD2, and it acts as a scaffold/RGS-domain inhibitor of Gαq and WNT/APC signaling, and as an inhibitor of MALT1 protease activity; in the primary cilium GRK2 phosphorylates Smoothened to enable direct PKA catalytic subunit binding and Hedgehog pathway activation; and its subcellular localization to mitochondria (Ser670-dependent), centrosomes, and lamellipodia underlies cell-type-specific roles in metabolism, cell division, and migration.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GRK2 is a multifunctional serine/threonine kinase that initiates agonist-dependent GPCR desensitization and, beyond this canonical role, acts as a phosphorylation- and scaffold-based regulator of cell migration, division, metabolism, developmental signaling, and circadian and pain physiology [#28, #15, #4]. In its receptor-directed mode, GRK2 is the primary kinase driving \\u00b5-opioid receptor internalization and \\u03b2-arrestin2 recruitment [#28], selectively phosphorylates C-terminal serines of agonist-activated receptors such as NTSR1 in a lipid-influenced manner [#15], and can be recruited directly by receptors (e.g. the D2 dopamine receptor) in a G-protein-independent fashion to bias signaling toward \\u03b2-arrestin [#27]; a cryo-EM structure of the NTSR1\\u2013GRK2\\u2013G\\u03b1q complex shows the GRK2 N-terminal helix docking into the receptor cytoplasmic pocket analogously to G protein, with the biased ligand SBI-553 binding the GRK2\\u2013NTSR1 interface to favor GRK2 over G\\u03b1q [#3]. GRK2 catalytic competence depends on a C-tail conformational switch (Val477) that acquires the closed active state upon receptor engagement [#19] and on acidic phospholipid cofactors that activate the kinase while PIP2 inhibits it [#11]. GRK2 also acts through its RGS domain to sequester activated G\\u03b1q/11, negatively regulating insulin-stimulated GLUT4 translocation, and to bind APC and inhibit canonical WNT/\\u03b2-catenin signaling [#5, #14]. A broad set of non-receptor substrates extends its reach: GRK2 phosphorylates and activates HDAC6 to promote tubulin deacetylation, lamellipodial motility, and (via HDAC6/Pin1 deacetylation) tumor proliferation [#4, #16]; phosphorylates p38 MAPK at Thr123 to dampen p38 signaling [#12]; activates Mst2 to drive centrosome separation [#13]; and phosphorylates ENaC and its regulator Nedd4/Nedd4-2, the mRNA-binding protein HuR, SAV1 in the Hippo\\u2013YAP pathway, and PERIOD2 to set circadian period [#6, #18, #32, #35, #25]. In the primary cilium GRK2 relocates to the ciliary shaft upon Smoothened activation, phosphorylates SMO, and enables active SMO to bind and inactivate the PKA catalytic subunit, transducing Hedgehog signaling [#22, #21]. GRK2 activity, levels, and localization are tightly controlled: PKC at Ser29 relieves calmodulin inhibition [#2], ERK and CDK2 at Ser670 impair kinase activity, trigger Pin1-dependent degradation during G2/M, and direct mitochondrial translocation after cardiac ischemia-reperfusion [#1, #2, #7, #20]; c-Src tyrosine phosphorylation enhances G\\u03b1q binding [#9]; and RKIP serves as a physiological inhibitor that sequesters GRK2 from receptors following PKC-dependent activation [#0, #26]. Loss-of-function mutations in GRK2 cause Jeune syndrome (asphyxiating thoracic dystrophy) through failed cilia-based Hedgehog signaling and failed phosphorylation of the WNT co-receptor LRP6 [#23].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that GRK2 catalytic activity toward GPCRs is not intrinsic but conditioned by membrane lipids, defining a biochemical activation requirement.\",\n      \"evidence\": \"Mixed-micelle phosphorylation, photoaffinity crosslinking and kinetics on \\u03b22AR\",\n      \"pmids\": [\"7673171\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the lipid-induced conformational change not resolved\", \"PIP2 inhibition mechanism not defined at residue level\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated that GRK2 cooperates with \\u03b2-arrestin1 to desensitize a GPCR, anchoring its canonical receptor-uncoupling role functionally.\",\n      \"evidence\": \"Co-transfection of TSH receptor with GRK2/\\u03b2-arrestin1, cAMP and proliferation assays\",\n      \"pmids\": [\"8885248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor phosphorylation sites not mapped\", \"Overexpression system may not reflect endogenous stoichiometry\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified the first non-receptor GRK2 substrate (tubulin), opening the concept that GRK2 acts beyond GPCR desensitization.\",\n      \"evidence\": \"GST pulldown, in vitro kinase assay, co-purification with tubulin\",\n      \"pmids\": [\"9716377\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of tubulin phosphorylation in cells not established\", \"Single-lab in vitro reconstitution\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed that ERK1/2 phosphorylation at Ser670 is a feedback brake that impairs GRK2 receptor phosphorylation and G\\u03b2\\u03b3 activation, establishing kinase regulation of the kinase.\",\n      \"evidence\": \"Mass spectrometry site ID, mutagenesis, in vitro ERK1 assay, HEK293 activity assays\",\n      \"pmids\": [\"10574913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address downstream localization or degradation consequences of S670 phosphorylation\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined PKC phosphorylation of Ser29 as the switch that relieves tonic calmodulin inhibition, linking PKC activity to GRK2 activation.\",\n      \"evidence\": \"In vitro PKC assay, peptide mapping, S29A mutagenesis, calmodulin binding assay\",\n      \"pmids\": [\"11042191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular contexts where calmodulin inhibition dominates not delineated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified RKIP as a physiological inhibitor that, upon PKC phosphorylation, switches from Raf-1 to GRK2 to block receptor internalization, providing endogenous GRK2 regulation.\",\n      \"evidence\": \"Reciprocal Co-IP, PKC phosphorylation, RKIP knockdown, cardiomyocyte function\",\n      \"pmids\": [\"14654844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of RKIP across receptor types not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established the RGS domain of GRK2 as a G\\u03b1q/11 sequestration module that negatively regulates insulin/GLUT4 metabolism independent of kinase activity.\",\n      \"evidence\": \"Antibody microinjection, siRNA, RGS-deletion mutant, glucose uptake in 3T3-L1 adipocytes\",\n      \"pmids\": [\"15241473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural basis of G\\u03b1q sequestration in this context not shown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed GRK2 phosphorylates the ENaC \\u03b2-subunit to render the channel Nedd4-2-insensitive, extending GRK2 to ion transport regulation.\",\n      \"evidence\": \"Xenopus oocyte electrophysiology, in vitro kinase assay, co-expression\",\n      \"pmids\": [\"15284439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosite on ENaC \\u03b2 not precisely mapped in original finding\", \"In vivo relevance to sodium handling not established here\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined c-Src tyrosine phosphorylation (Y13/86/92) of the RGS region as a positive modulator of G\\u03b1q binding, adding tyrosine-kinase control of GRK2.\",\n      \"evidence\": \"Co-IP, tyrosine site mutagenesis, phosphomimetic, M1 receptor/PLC-\\u03b2 signaling\",\n      \"pmids\": [\"16725308\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; physiological c-Src context not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified Nedd4/Nedd4-2 as direct GRK2 substrates, providing a mechanistic link between GRK2 and ubiquitin-ligase control of sodium transport.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, phosphosite identification (Thr466)\",\n      \"pmids\": [\"17544362\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional impact on Nedd4 ligase activity not quantified\", \"Limited follow-up\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected ERK/CDK2-driven Ser670 phosphorylation to Pin1-dependent proteasomal degradation during G2/M, showing GRK2 turnover gates cell cycle progression.\",\n      \"evidence\": \"Cell synchronization, CDK2 in vitro phosphorylation, S670A mutagenesis, Pin1 Co-IP, flow cytometry\",\n      \"pmids\": [\"20080565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating Ser670/Pin1-dependent degradation not identified here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed a kinase-independent scaffolding role: GRK2 binds PTCH1 to release cyclin B1 nuclear translocation, required for embryonic development.\",\n      \"evidence\": \"Zebrafish morpholino, kinase-dead rescue, Co-IP, domain mapping\",\n      \"pmids\": [\"19502428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mammalian relevance of PTCH1\\u2013cyclin B1 control not demonstrated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established GRK2 as a centrosomal kinase that activates Mst2 to drive EGFR-mediated centrosome separation, linking GRK2 to mitotic architecture.\",\n      \"evidence\": \"Immunofluorescence localization, knockdown, in vitro Mst2 phosphorylation, dominant-negative\",\n      \"pmids\": [\"23904266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; centrosomal recruitment mechanism unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed GRK2 phosphorylates p38 MAPK at Thr123 to impair MKK6 binding and p38 activation, defining a kinase-substrate node dampening inflammatory signaling.\",\n      \"evidence\": \"In vitro kinase assay, T123E mutagenesis, MKK6 Co-IP, GRK2+/- macrophage cytokine assays\",\n      \"pmids\": [\"18437630\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous stoichiometry of p38 phosphorylation by GRK2 unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a kinase-activity-dependent RGS-domain interaction with APC that inhibits canonical WNT/\\u03b2-catenin signaling, broadening GRK2 into developmental signaling.\",\n      \"evidence\": \"Wnt luciferase reporter, Co-IP, siRNA, RGS-deletion, \\u03b2-catenin imaging in osteoblasts\",\n      \"pmids\": [\"19556343\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How kinase activity enables a scaffolding interaction not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the C-tail residue Val477 as required for acquiring the closed active kinase conformation upon receptor engagement, providing a conformational activation mechanism.\",\n      \"evidence\": \"Structure-guided mutagenesis, kinetic analysis, rhodopsin/\\u03b22AR phosphorylation\",\n      \"pmids\": [\"19338266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct structural snapshot of the closed state not provided in this study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated cell-type-specific GRK2 dosage controls chronic pain: reduced microglial GRK2 converts acute to chronic hyperalgesia via p38/TNF-\\u03b1.\",\n      \"evidence\": \"Cell-specific conditional knockdown, hyperalgesia models, intrathecal pathway inhibition\",\n      \"pmids\": [\"20147541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular substrate of GRK2 in microglia not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified HDAC6 as a GRK2 substrate whose activation promotes tubulin deacetylation and cell motility, with Ser670 phosphorylation potentiating the interaction.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro kinase assay, K220R/S670A mutagenesis, live-cell imaging, migration assay\",\n      \"pmids\": [\"22193721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HDAC6 phosphosite(s) targeted by GRK2 not pinpointed here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed the GRK2/EPAC1 balance in nociceptors determines transition to chronic pain, establishing GRK2 as a rheostat in pain priming.\",\n      \"evidence\": \"Viral GRK2 gene transfer, Epac1 heterozygous/antisense mice, two priming models\",\n      \"pmids\": [\"24231349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between GRK2 levels and cAMP/EPAC1 not biochemically defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected insulin signaling to GRK2-mediated \\u03b22AR desensitization via IRS2-dependent recruitment, linking metabolic and adrenergic signaling in heart.\",\n      \"evidence\": \"Co-IP, \\u03b22AR phosphorylation/internalization, cAMP, IRS2 KO cardiomyocytes, contractility\",\n      \"pmids\": [\"25460042\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; molecular detail of IRS2\\u2013GRK2 coupling incomplete\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Refined GRK2 substrate selectivity, showing agonist- and lipid-dependent C-terminal serine phosphorylation of NTSR1 differing from \\u03b22AR/\\u00b5OR consensus rules.\",\n      \"evidence\": \"Nanodisc phosphorylation, MS phosphosite mapping, NTSR1 mutagenesis\",\n      \"pmids\": [\"26120872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of lipid-tuned phosphosite selection across receptors unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed GRK2 in the circadian machinery by phosphorylating PERIOD2 at Ser545 and suppressing mPeriod1 transcription to modulate clock period and amplitude.\",\n      \"evidence\": \"Grk2-deficient mouse rhythms, SCN electrophysiology, PER1/2 Co-IP, in vitro phosphorylation, reporter assay\",\n      \"pmids\": [\"26279567\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of transcriptional suppression of Period1 not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established a GRK2/HDAC6/Pin1 axis promoting breast cancer proliferation, linking GRK2's HDAC6 activation to oncogenic Pin1 stabilization.\",\n      \"evidence\": \"Co-IP, knockdown/overexpression, in vitro HDAC6 phosphorylation, Pin1 acetylation, xenograft\",\n      \"pmids\": [\"27720394\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; relative contribution of this axis among GRK2 oncogenic functions unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated GRK2 kinase activity is essential for Hedgehog signaling downstream of Smoothened in vivo, placing GRK2 in the Hh pathway.\",\n      \"evidence\": \"Zebrafish grk2-null, kinase-dead rescue, Smo phosphomimetic/phospho-null analysis\",\n      \"pmids\": [\"27113758\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism downstream of Smo phosphorylation not resolved in this study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified the ciliary/serotonergic role via the GRK2 ortholog phosphorylating monoamine oxidase AMX-2 in C. elegans, controlling serotonin metabolism and egg-laying.\",\n      \"evidence\": \"C. elegans grk-2 genetics, metabolite measurement, Co-IP, kinase-dead rescue\",\n      \"pmids\": [\"28213524\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mammalian MAO regulation by GRK2 not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed EIF3d stabilizes GRK2 by blocking ubiquitin-mediated degradation, activating PI3K/Akt to drive gallbladder cancer, adding a translation-factor controller of GRK2 levels.\",\n      \"evidence\": \"Co-IP, ubiquitination/stability assays, PI3K/Akt western, in vitro/in vivo cancer assays\",\n      \"pmids\": [\"28594409\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase blocked by EIF3d not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated D2R can directly recruit GRK2 G-protein-independently to drive \\u03b2-arrestin signaling, refining the concept of GRK2-driven biased agonism.\",\n      \"evidence\": \"BRET recruitment, biased D2R mutants, biased ligand UNC9994, G-protein blockade\",\n      \"pmids\": [\"29487132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of direct GRK2 recruitment not defined here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined Ser670 phosphorylation as the determinant of GRK2 mitochondrial translocation after ischemia-reperfusion, linking GRK2 to cardiomyocyte metabolic injury.\",\n      \"evidence\": \"S670A knock-in mice, cardiac IR model, mitochondrial respiration, PDH activity\",\n      \"pmids\": [\"30538174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mitochondrial substrate(s) of GRK2 not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped phosphorylation-triggered proteasomal (ischemia) and calpain (reperfusion) degradation of GRK2, showing GRK2 turnover modulates AKT-dependent cardioprotection.\",\n      \"evidence\": \"Rat/porcine heart IR, proteasome/calpain inhibitors, Pin1/AKT analysis\",\n      \"pmids\": [\"31594751\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific phosphosites driving each degradation route not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed calpain raises GRK2 levels by degrading its ligase MDM2 and via NF-\\u03baB transcription, mechanistically tying GRK2 abundance to cardiac hypertrophy.\",\n      \"evidence\": \"Calpain inhibitor in rats, GRK2 hemizygous mice, MDM2/NF-\\u03baB/I\\u03baB assays, mRNA quantification\",\n      \"pmids\": [\"30915659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct MDM2-mediated GRK2 ubiquitination not shown in this study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established with CRISPR knockouts that GRK2 is the dominant kinase for \\u00b5-OR internalization and \\u03b2-arrestin2 recruitment, quantifying its primacy among GRKs.\",\n      \"evidence\": \"GRK2/GRK3/double KO HEK293, internalization and \\u03b2arr2 recruitment, rescue, CMPD101\",\n      \"pmids\": [\"33060647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the GRK2/3-independent sustained recruitment component unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated GRK2 binds the MALT1 death domain to inhibit its scaffolding and protease activities, suppressing NF-\\u03baB and acting as a tumor suppressor in ABC-DLBCL.\",\n      \"evidence\": \"Co-IP/domain mapping, MALT1 protease assay, NF-\\u03baB reporter, knockdown, tumor models\",\n      \"pmids\": [\"31961340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether GRK2 kinase activity contributes to MALT1 inhibition not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed GRK2 phosphorylates HuR to enhance its cytoplasmic shuttling and HIF-1\\u03b1 mRNA binding under hypoxia, linking GRK2 to post-transcriptional control.\",\n      \"evidence\": \"In vitro phosphorylation, phosphodefective HuR mutants, RIP for HIF-1\\u03b1 mRNA, fractionation\",\n      \"pmids\": [\"32413989\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HuR phosphosite(s) targeted by GRK2 not precisely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established a peripheral neuronal switch in which GRK2 tonically inhibits delta opioid receptor until PKC-phosphorylated RKIP sequesters it, restoring receptor function.\",\n      \"evidence\": \"Sensory neuron Co-IP, DOR functional assay, PKC inhibition, GRK2-RKIP pulldown\",\n      \"pmids\": [\"27568556\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; generalizability to other receptors not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Distinguished GRK isoform specificity in cardiomyocytes, with GRK2 phosphorylating and desensitizing GPER, refining receptor-selective GRK roles.\",\n      \"evidence\": \"CRISPR GRK5 deletion, Co-IP, MR reporter, GRK2 pharmacological inhibition, ventricular myocytes\",\n      \"pmids\": [\"32326036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GRK2\\u2013GPER phosphosites and functional output not detailed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked GRK2 loss-of-function mutations to Jeune syndrome through failed cilia-based Hedgehog and LRP6-dependent canonical Wnt signaling, providing a human disease mechanism.\",\n      \"evidence\": \"Patient-derived GRK2-null cells, chondrocyte differentiation, Hh/Wnt reporters, LRP6 phosphorylation\",\n      \"pmids\": [\"33200460\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct evidence that GRK2 phosphorylates LRP6 in vivo limited\", \"Genotype\\u2013phenotype range not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed GRK2 desensitizes platelet ADP receptors P2Y1/P2Y12 and binds endogenous G\\u03b2\\u03b3, establishing its role in thrombosis and Ca2+/Rap1/Akt signaling.\",\n      \"evidence\": \"Platelet-specific GRK2 KO, laser thrombosis model, Ca2+/Rap1/Akt assays, G\\u03b2\\u03b3 Co-IP\",\n      \"pmids\": [\"35793439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ADP-receptor phosphosites by GRK2 not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided a high-resolution structural basis for GRK2 receptor engagement and biased agonism, showing the GRK2 N-helix docks into the receptor pocket and SBI-553 clashes with G\\u03b1q.\",\n      \"evidence\": \"Cryo-EM of NTSR1\\u2013GRK2\\u2013G\\u03b1q with SBI-553\",\n      \"pmids\": [\"37532940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational transitions during catalysis not captured\", \"Generalizability across receptor classes untested structurally\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified SAV1 as a GRK2 substrate whose phosphorylation drives its degradation, impairing Hippo-YAP and promoting synovial fibroblast proliferation in arthritis.\",\n      \"evidence\": \"Co-IP, SAV1 ubiquitination, YAP phosphorylation/translocation, CIA rat model\",\n      \"pmids\": [\"38486990\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SAV1 phosphosite(s) and responsible E3 ligase not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved the ciliary Hedgehog mechanism: GRK2 relocates to the ciliary shaft, phosphorylates SMO, and enables active SMO to bind and inactivate PKA-C, completing the Hh transduction step.\",\n      \"evidence\": \"Live-cell ciliary imaging, reconstitution, SMO phosphorylation, PKA-C binding, zebrafish/mouse models\",\n      \"pmids\": [\"39138140\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger for GRK2 ciliary relocalization not fully defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GRK2's many context-specific functions are coordinated\\u2014which substrates, scaffolds, and localization cues dominate in a given cell type and how the phosphorylation code on GRK2 itself selects among them\\u2014remains unresolved.\",\n      \"evidence\": \"No single study integrates the receptor, RGS-scaffold, non-receptor substrate, and localization programs\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying model linking GRK2 regulatory phosphosites to substrate/localization choice\", \"Stoichiometry and competition among partners in vivo unknown\", \"Structural states beyond the receptor-bound complex uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4, 6, 12, 13, 15, 18, 22, 25, 32, 35]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2, 10, 11, 19, 17, 28]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 14, 8, 33]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [28, 27, 37, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [22, 23]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [26, 34, 3]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [4, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 28, 27, 37]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 14, 21, 22, 23]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [7, 13]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 33, 38]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RKIP\", \"HDAC6\", \"Pin1\", \"GNAQ\", \"APC\", \"PTCH1\", \"MALT1\", \"GBG\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}